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Background: The human immunodeficiency virus (HIV) affects the central nervous system 
(CNS) causing a spectrum of neuropsychological impairment known as HIV-Associated 
Neurocognitive Disorders (HAND). Although highly active antiretroviral therapy (HAART) has 
decreased the incidence of HIV dementia, the milder forms of HAND have increased in 
prevalence. This suggests incomplete CNS viral control and potential drug toxicity. The CNS 
penetration-effectiveness (CPE) of HAART regimens may be an important factor. Additionally, 
there is need for biomarkers of HAND, to identify patients before the onset of functionally 
significant disease, for earlier treatment, and to monitor response. 
 
Aims: This study aimed to determine whether HAART improved cognitive function in HIV 
positive people in South Africa, and whether this effect differed according to the CPE of the 
regimen used. I also investigated potential HAND biomarkers (serum neopterin, osteopontin 
and neurofilament H) to determine their relationship to the severity of cognitive impairment at 
baseline in HAART-naïve patients, and whether initial levels of these biomarkers related to the 
change in cognitive function a year later.  
 
Methods: I reviewed 125 HIV positive patients with varying degrees of cognitive function, who 
were assessed initially (pre-HAART) and were followed up a year later. A neuropsychological 
test battery was administered at both visits to derive two sets of global deficit scores (GDS). 
Some of the participants remained HAART-naïve throughout this period, thereby providing a 
comparison for the effects of HAART. I measured biomarker levels, using immuno-assays, on 
stored serum samples from the baseline assessment.  
 
Results:  More HAART recipients maintained or improved cognitive function, and had greater 
beneficial change in GDS after one year, than those not on HAART. No significant difference in 
cognitive response was found between the higher and lower CPE HAART regimen groups. 
Neopterin levels were higher in the HIV positive group than in the HIV negative controls. 
Neopterin did not relate to baseline cognitive function in the HIV positive group. However, 
higher baseline neopterin levels were associated with maintenance of, or improvement in, 
cognitive function after one year. Osteopontin levels did not differ significantly between the 
HIV positive and negative groups, but did relate to cognitive function in the HIV positive group, 
with highest levels found in the severely impaired. Baseline osteopontin was not associated 











Conclusions: This study showed that HAART was beneficial for cognitive function, and that 
regimen CPE did not affect cognitive outcomes after one year. This is a promising finding in the 
protocol-bound South African context, where the current first-line HAART regimen has a low 
CPE rating. Serum neopterin and osteopontin levels may have clinical use; however, further 
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Chapter 1 – Introduction 
 
The human immunodeficiency virus (HIV) is a retrovirus, belonging to the subfamily of 
lentiviruses, which are well known for their neurovirulence (Grant 2008; Haase 1986). The 
primary effects of HIV on the nervous system were noted early on in our experience with the 
disease (Grant et al. 1987; Snider et al. 1983; Ho et al. 1985, Gabuzda et al. 1987), yet the 
exact pathogenic mechanisms remain unclear. It seems that the central nervous system (CNS) 
is invaded early by HIV particles, although clinical effects are generally only seen later with 
advanced immunosuppression (Grant et al. 1987). The viral invasion of the CNS has both direct 
and indirect effects, yet most of the neurotoxicity seems to result from the indirect effects, 
namely, ongoing neuro-inflammation (Hult et al. 2008). The result of this neurotoxicity is a 
clinical spectrum of impairment, collectively known as HIV-associated neurocognitive disorders 
(HAND). 
 
Highly active antiretroviral therapy (HAART) has had a dramatic effect on HIV infection 
worldwide, allowing for the systemic control of viral replication, which in turn allows for at 
least partial regeneration of the immune system. HAART has been less successful in terms of 
CNS disease. Although there has been a decrease in the incidence of the most severe form of 
HIV CNS disease, HIV dementia (HAD), the milder forms of cognitive impairment have actually 
increased in prevalence (McArthur 2004; Heaton et al. 2010). This is in part attributable to 
longer lifespan secondary to treatment with HAART, and potentially increased awareness and 
diagnosis of the problem. However, it also suggests incomplete control of the virus and its 
effects within the CNS, and potentially, neurotoxicity of the antiretrovirals (ARVs) themselves 
(Robertson et al. 2010). 
 
The issue of treatment of HAND is therefore currently an important research area. Questions 
include the optimal choice of ARV agents, the timing of ARV initiation, as well as whether 
additional agents are required, perhaps targeting some of the other proposed pathogenic 
mechanisms. 
 
In this regard, there is a need for biomarkers of HAND, which can identify susceptible patients 
before the onset of functionally significant disease, to be able to target them for earlier or 
additional treatment.  Studies of such biomarkers could also help to elucidate the 











I therefore undertook to test a few potential biomarkers for HAND, in our setting, to assess 
whether they had any associative or predictive qualities.  A largely retrospective review was 
undertaken of a cohort of HIV positive patients with varying degrees of cognitive impairment, 
who were seen initially at baseline, pre-HAART, and were then followed up after a period of 
one year. Some of these patients remained ARV-naïve throughout this period and therefore 
provided a useful group for comparison to determine the effects of HAART. Biomarker levels 
were measured on stored serum samples from the baseline assessment. I planned to assess 
the effect of HAART on cognitive status, and whether this status and its potential change 
showed any association with the initial measured biomarker levels. Furthermore, I wished to 
examine whether the CNS penetration-effectiveness of the antiretroviral regimen used, had 











Chapter 2 – Rationale and motivation:  
Background to the study with review of the literature 
 
2.1 Introduction to chapter 
 
This chapter aims to provide the reader with a background understanding of the HIV-
Associated Neurocognitive Disorders, according to the current literature. It covers 
pathogenesis, clinical features, risk factors, diagnosis, and management of HAND in general, 
before focussing on HAND in the South African context. Finally the concept of biomarkers is 
introduced, followed by a discussion of current HAND biomarker research.  
 
Most of this HAND literature has been based on studies conducted in Europe, North America 
and Australia. This is important as these regions represent developed world contexts, with a 
much lower prevalence and a different predominant subtype of HIV-1 to that found in South 
Africa. This could mean that our experience with HAND is different. 
 




2.2.1.1 Mechanisms of injury 
 
The pathogenesis of HAND is still not yet fully understood. It is commonly accepted that HIV 
causes neuronal injury through direct viral effects, but also to a greater extent, through the 
inflammatory cascade which is created as a result of its presence within the central nervous 
system (Hult et al. 2008).  
 
The process is thought to start with the early invasion of HIV particles into the CNS (Ho et al. 
1985; Brew et al. 1989) typically arriving inside infected monocyte-derived macrophages 
(“Trojan Horse Theory”) (Anthony et al. 2008; Gonzalez-Scarano et al. 2005; Haase 1986). 
These cells traverse the blood-brain barrier (BBB) as part of routine immune surveillance, yet 











structural and functional disruption of the blood-brain barrier (BBB). This disruption of the BBB 
is mediated by inflammatory cytokines and the viral proteins gp120 (glycoprotein 120) and Tat 
(Transactivator of Transcription) (Hult et al. 2008; de Vries et al. 1997; Kanmogne et al. 2002).  
 
It has also been suggested that transcytosis and endothelial cell infection are mechanisms of 
entry into the CNS, yet probably occurring to a much smaller degree (Bomsel 1997; Banks et al. 
2001; Liu et al. 2002; Bobardt et al. 2004; Edinger et al. 1997; Gonzalez-Scarano et al. 2005).   
 
Once inside the brain parenchyma, the HIV particles infect perivascular macrophages and 
tissue microglia, via interaction with their CD4 and CCR5 receptors (Hult et al. 2008). This 
infection may initially be latent, until advanced immunosuppression occurs. These cells then 
become productive of HIV particles in their own right, and also begin to secrete a variety of 
inflammatory cytokines. These chemicals in turn, cause neuronal injury, dendritic damage and, 
ultimately, apoptosis of neurons. The latter process occurs primarily through excitotoxicity 
with over-activation of n-methyl-d-aspartate (NMDA)-coupled ion channels, excess influx of 
calcium and oxidative stress (Hult et al. 2008).  
 
Astrocytes may also be infected by HIV, via unclear mechanisms. They do not have CD4 
receptors, but they do have the chemokine co-receptors CCR5 and CXCR4. This infection 
however, is restricted, in that it does not lead to production of new virions.  The important 
supportive functions of the astrocytes, namely buffering of neurotransmitter levels and the 
production of neurotrophic factors, do however become disrupted and there may be 
arachidonic acid and nitric oxide release (Anthony et al. 2008).  
 
Many of the HIV proteins have toxic effects (Ghafouri et al. 2006). Tat promotes an increase in 
neuronal intracellular calcium, the development of reactive oxygen species and caspase 
activation, leading to apoptosis. It also affects endothelial permeability causing blood-brain 
barrier dysfunction, and stimulates further cytokine production by macrophages and microglia 
(Ghafouri et al. 2006). Viral protein R (Vpr) causes cell cycle arrest at the G2/M phase, which 
leads to cell death. It may also alter mitochondrial permeability (Ghafouri et al. 2006). Gp120 
has direct neurotoxic effects by interacting with the NMDA receptor and disrupting neuronal 
calcium homeostasis (Ghafouri et al. 2006). It also has indirect effects by stimulating cytokine 
production from macrophages and arachidonic acid from astrocytes (Ghafouri et al. 2006).  












Although the virus and its products have direct neurotoxic effects, the inflammatory cascade 
that is initiated appears to cause the majority of the CNS damage (Hult et al. 2008).  This 
concept is supported by a study by Glass et al. (1995) which showed that the number of 
activated microglia and macrophages is a better correlate for HIV-associated dementia than 
the number of HIV-infected cells in the brain.  It has also been suggested that this mechanism 
of inflammatory injury can be self-sustaining in a “hit and run” type phenomenon (Nath et al. 
1999; Brew et al. 2008). This means that once initiated by the presence and effect of HIV 
particles, the inflammatory cascade within the CNS could remain activated, even if the HIV 
particles are largely removed by the effects of HAART. This could have implications for the 
treatment of HAND.  
 
An alternative model has been suggested more recently. Gartner (2000) proposes that 
abnormal systemic inflammation in late stage AIDS leads to the production of increased 
macrophage-colony stimulating factor, which causes altered monocyte production in the bone 
marrow, with an increase in the CD14+CD16+ subset. This subset usually makes up about 6% 
of monocytes, but in late AIDS has been found to be about 16%, and in patients with HAD, 
about 37%. These cells are extremely neuro-invasive and release high levels of pro-
inflammatory cytokines (especially tumour necrosis factor alpha and interleukin 1-beta). It is 
thought that it is the invasion of these cells into the CNS late in the course of the disease, and 
the resultant neuro-inflammation that is induced, that leads to the damage associated with 
clinical HAND.  
 
2.2.1.2 Pathological correlates 
 
Many pathological changes have been identified in the brains of HIV infected persons; most 
commonly HIV encephalitis (HIVE). The characteristic features of HIVE are multinucleated giant 
cells, perivascular macrophage accumulation, astrocytic hyperplasia, and microglial nodules 
(Anthony et al. 2008). Other findings include generalised atrophy (secondary to neuronal 
apoptosis and white matter rarefaction), myelin pallor, and dendritic, synaptic and axonal 
damage (Anthony et al. 2008). Of these changes, synapto-dendritic damage correlates best 















2.2.1.3 Sites of involvement 
 
Any area of the brain could be affected in theory, however the sites predominantly affected 
appear to be the basal ganglia, the central white matter and the frontal cortex (Anthony et al. 
2008; Langford et al. 2003). These sites correlate with the presentation of a sub-cortical 
dementia. Morphometric studies have shown a 40% reduction in brain tissue density in the 
frontal and temporal regions of the brain (Ketzler et al. 1990; Masliah et al. 1992a), and a 50-
90% reduction in the hippocampus (Masliah et al. 1992b). Immunochemistry studies have 
shown that the areas worst affected in terms of synapto-dendritic damage are the striatum 
and hippocampus (Moore et al. 2006).  
 
 
    
Figure 2.1: Mechanisms of neurodegeneration and neuroprotection in AIDS  
 
From: Gonzalez-Scarano F, Martin-Garcia J. The Neuropathogenesis of AIDS. Nature Reviews    












2.2.2 Clinical features 
 
2.2.2.1 Typical clinical picture 
 
HIV-associated CNS dysfunction is a clinical spectrum which presents typically with cognitive, 
motor and behavioural features (McArthur et al. 2005). In its initial stages the impairments 
may be subtle, and are often overlooked or misdiagnosed as depression (Grant 2008).  
 
Early features may include “short-term” (episodic) memory loss, mental slowing, 
comprehension difficulties and apathy. Signs that may be detectable include mild gait 
disturbance, tremor, impairment of fine manual dexterity, impairment of rapid eye and limb 
movements, hyperreflexia, hypertonia and frontal release signs. Of note, apraxias and aphasias 
are typically absent (Grant 2008; Ghafouri et al. 2006). In terms of neuropsychological 
impairment, psychomotor speed, memory and executive function are usually worst affected in 
the initial stages.  
 
Later on the cognitive deficits become more widespread, with the overall clinical picture that 
of a sub-cortical dementia. This is often accompanied by features of a symmetrical distal 
sensory polyneuropathy, also due to the effects of HIV, on the peripheral nervous system 
(McArthur et al. 2005).   
 
HIV infection can also result in other pathology in the nervous system, through its indirect 
effects such as immune suppression or immune dysfunction, which allows for opportunistic 
infections, neoplasia and autoimmune disorders (see Figure 2.2).            
















      Figure 2.2: The effects of HIV on the nervous system 
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2.2.2.2 Clinical course 
 
The clinical course of this disorder has changed with the introduction of HAART therapy 
(Woods et al. 2009). In the pre-HAART era, the condition typically took the form of a sub-acute 
progressive dementia, often leading to death within six months (Bouwman et al. 1998). This 
pattern would still be true for untreated patients.  
 
This contrasts with the situation in HAART-treated patients. Firstly, the life expectancy after a 
diagnosis of HAD is now considerable longer; 39.6 months in one study in Australia (Dore et al. 
2003). Secondly, milder forms of cognitive impairment are now much more prevalent than 
actual dementia, and thirdly, different forms of HAD are now recognisable (Nath et al. 2008). A 
more slowly progressive dementia may be found in patients on HAART who have incomplete 
virological control, this could be termed chronic active dementia. Patients with virological 
suppression on HAART, with stable neurological signs and symptoms and possibly even some 
recovery, could be said to have chronic inactive dementia. Patients on effective HAART therapy 
may experience a major improvement in terms of cognitive function, and could even be said to 
have had reversible dementia. This classification is entirely clinical and can only be applied 
retrospectively.  
 
Probably the most significant change in the HAART era has been the increase in prevalence of 





As mentioned above, HIV-induced neurotoxicity within the CNS results not in a single clinical 
disorder but rather, a spectrum of cognitive impairment. Creating clinical definitions has been 
a challenge since the mid 1980s, when it was recognised that HIV-related CNS disorders were 
not limited to opportunistic infections, and that the virus itself was able to enter the CNS and 
cause pathology. At this stage it was noted to result in a syndrome of cognitive and motor 
dysfunction - a sub-cortical dementia - that generally progressed fairly rapidly and often led to 
death (Navia et al. 1986). This was termed the AIDS dementia complex or HIV Dementia, and 
became included as a Centers for Disease Control (CDC) AIDS defining condition in 1987 
(Rackstraw 2011; Grant 2008). 
 
In 1991 the classification expanded to incorporate a seemingly similar, but far milder form of 











HIV-associated dementia complex and minor cognitive motor disorder. HIV-associated 
dementia complex implied severe cognitive, motor and or emotional or personality 
disturbances with marked impact on everyday life, whilst in minor cognitive motor disorder 
the symptoms were far milder and had less functional impact. The major criticisms of this 
classification were that it was too loosely defined (meaning a diagnosis of dementia could be 
made without severe cognitive symptoms) and that it did not recognise an entity of cognitive 
impairment which was subtle enough not to impair everyday function. 
 
Therefore the classification was updated by an AAN working group assembled in Italy in 2005, 
with the support of the United States National Institutes of Health. The results of this meeting 
were published by Antinori et al. in 2007, and detail the new widely accepted clinical 
definitions for HIV-associated Neurocognitive Disorders (Antinori et al. 2007) (See Table 2.1). 
 
Asymptomatic Neurocognitive Impairment (ANI) is defined as “acquired impairment in 
cognitive functioning, involving at least two ability domains, documented by performance of at 
least 1.0 SD below the mean for age-education-appropriate norms on standardised 
neuropsychological tests.” (Antinori et al. 2007). This testing should cover language ability, 
attention/working memory, abstraction/executive function, memory (learning and recall), 
speed of information processing, sensory-perceptual and motor skills. Importantly, in this 
category, the cognitive impairment has no noticeable impact on everyday functioning. This 
contrasts with Mild Neurocognitive Disorder (MND) which is also an impairment of at least 1.0 
SD below the mean, but produces at least mild interference with daily functioning.  
 
HIV-1-associated Dementia (HAD) is a “marked acquired impairment in cognitive functioning, 
involving at least two ability domains; typically the impairment is in multiple domains, 
especially in learning of new information, slowed information processing, and defective 
attention/concentration.” The impairment is objectively measured as at least 2 SD below the 
demographically corrected mean. The impairment produces marked interference with daily 
functioning (Antinori et al. 2007).  
 
Across all of the categories, there must be no pre-existing cause or other explanation for the 
cognitive impairments, other than HIV, and no delirium (Antinori et al. 2007). Motor difficulties 
were initially considered to be cardinal in the diagnosis of HIV-associated dysfunction, but 
more recently it has been decided that the cognitive features are more central, hence the 












HIV-associated asymptomatic neurocognitive impairment (ANI)* 
1. Acquired impairment in cognitive functioning, involving at least two ability domains, documented by 
performance of at least 1.0 SD below the mean for age-education-appropriate norms on standardized 
neuropsychological tests. The neuropsychological assessment must survey at least the following 
abilities: verbal/language, attention/working memory, abstraction/executive, memory (learning, recall), 
speed of information processing, sensory-perceptual, motor skills 
2. The cognitive impairment does not interfere with everyday functioning. 
3. The cognitive impairment does not meet criteria for delirium or dementia. 
4. There is no evidence of another pre-existing cause for the ANI*. 
* If there is a prior diagnosis of ANI, but currently the individual does not meet criteria, the diagnosis of ANI in remission can be 
made.  
* If the individual with suspected ANI also satisfies criteria for a major depressive episode or substance dependence, the 
diagnosis of ANI should be deferred to a subsequent examination conducted at a time when the major depression has remitted 
or at least 1 month after cessation of substance use.  
HIV-associated mild neurocognitive disorder (MND)** 
1. Acquired impairment in cognitive functioning, involving at least two ability domains, documented by 
performance of at least 1.0 SD below the mean for age-education-appropriate norms on standardized 
neuropsychological tests. The neuropsychological assessment must survey at least the following 
abilities: verbal/language, attention/working memory, abstraction/executive, memory (learning, recall), 
speed of information processing, sensory-perceptual, motor skills. 
Typically this would correspond to an MSK scale stage of 0.5 to 1.0. 
2. The cognitive impairment produces at least mild interference in daily functioning (at least one of the 
following): 
a) Self-report of reduced mental acuity, inefficiency in work, homemaking, or social functioning. 
b) Observation by knowledgeable others that the individual has undergone at least mild decline 
in mental acuity with resultant inefficiency in work, homemaking, or social functioning. 
3. The cognitive impairment does not meet criteria for delirium or dementia. 
4. There is no evidence of another pre-existing cause for the MND**. 
** If there is a prior diagnosis of MND, but currently the individual does not meet criteria, the diagnosis of MND in remission can 
be made.  
** If the individual with suspected MND also satisfies criteria for a severe episode of major depression with significant functional 
limitations or psychotic features, or substance dependence, the diagnosis of MND should be deferred to a subsequent 
examination conducted at a time when the major depression has remitted or at least 1 month after cessation of substance use. 
HIV-associated dementia (HAD) *** 
1. Marked acquired impairment in cognitive functioning, involving at least two ability domains, typically 
the impairment is in multiple domains, especially in learning of new information, slowed information 
processing, and defective attention/concentration. The cognitive impairment must be ascertained by 
neuropsychological testing with at least two domains 2 SD or greater than demographically corrected 
means. (Note that where neuropsychological testing is not available, standard neurological evaluation 
and simple bedside testing may be used, but this should be done as indicated in algorithm, see below)  
        Typically this would correspond to an MSK scale stage of 2.0 or greater. 
2. The cognitive impairment produces marked interference with day-to-day functioning (work, home life, 
social activities). 
3. The pattern of cognitive impairment does not meet criteria for delirium (e.g. clouding of consciousness 
is not a prominent feature); or, if delirium is present, criteria for dementia need to have been met on a 
prior examination when delirium was not present. 
4. There is no evidence of another pre-existing cause for the dementia (e.g. other CNS infection, CNS 
neoplasm, cerebrovascular disease, pre-existing neurologic disease, or severe substance abuse 
compatible with CNS disorder). *** 
***If there is a prior diagnosis of HAD, but currently the individual does not meet criteria, the diagnosis of HAD in remission can 
be made. 
*** If the individual with suspected HAD also satisfies criteria for a severe episode of major depression with significant 
functional limitations or psychotic features, or substance dependence, the diagnosis of HAD should be deferred to a subsequent 
examination conducted at a time when the major depression has remitted or at least 1 month has elapsed following cessation 
of substance use. Note that the consensus was that even when major depression and HAD occurred together, there is little 
evidence that pseudodementia exists and the cognitive deficits do not generally improve with the treatment of depression. 
 
Table 2.1: Revised research criteria for HIV-associated neurocognitive disorders (HAND) 
(modified from HIV Neurobehavioural Research Center criteria) 
 
From: Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M et al. Updated research nosology for HIV-











2.2.2.4 Neuropsychological Impairments 
 
It was accepted by the early 1980s that there were primary CNS complications associated with 
HIV. However, the idea of cognitive impairment which was directly due to the effects of HIV, 
including during the medically asymptomatic stages, remained controversial until 1987 when a 
comprehensive study on HIV-associated neurocognitive impairments was published by Grant 
et al. This study was conducted on ambulatory participants, in whom there was no clinical 
suspicion of an underlying neurological disease, and it provided evidence of multiple domains 
of cognitive impairment, across the spectrum of HIV disease. The most prominent 
abnormalities were in executive function, episodic memory and information processing speed 
(Grant et al. 1987). 
 
The neuropsychological impairments found in HIV disease have subsequently been well 
studied (Heaton et al. 1995 – see figure 2.3; Reger et al. 2002). It is now acknowledged that 
almost any cognitive ability could be compromised, but that there is a more typical pattern 
which tends to occur (Grant 2008). This pattern fits with the classification of HAND as an entity 
due predominantly to sub-cortical dysfunction.  
 
 
Figure 2.3: Prevalence of neuropsychological deficits in HIV positive subjects (percentage of 
subjects with impairments in these domains) 
 
From: Heaton RK, Grant I, Butters N, White D, Kirson D, Hampton Atkinson J et al. The HNRC 500 – 
Neuropsychology of HIV infection at different disease stages. Journal of the International 











Attention embraces a variety of functions, including focussing on a particular stimulus, whilst 
filtering out others, orientating to that stimulus and maintaining focus on it. Assessing one’s 
surroundings and focussing in on a stimulus needs to happen quite quickly, and is linked 
therefore to speed of information processing. There is also an overlap with working memory, 
as information needs to be maintained and manipulated to complete a task. Therefore tests of 
attention often have overlap with these two domains. Simple attention tasks (such as Trail 
Making Test A) can normally be quite easily completed by HIV positive individuals, whilst more 
complex attention tasks (such as the Digit Symbol Test), especially under time pressure, often 
present difficulty (Grant 2008; Vally 2011). 
 
Memory disturbance is prominent, especially episodic memory (Vally 2011). This is seen in 
difficulty with learning and the retrieval of new information (Grant 2008). Learning is the 
process by which new information is moved from immediate storage (working memory) to 
intermediate storage. There are two different kinds of memories at this stage: explicit and 
implicit memories.  
 
Explicit (also known as declarative) memory involves people, things, events or ideas whereas 
implicit (or procedural) memory relates to the learning of skills or procedures. Explicit memory 
in particular is found to be defective in HIV (Grant 2008). This can be evaluated with tests of 
logical memory such as the learning of stories, which is very sensitive to early HIV deficits 
(Grant 2008).  
 
From intermediate storage, information often needs to be consolidated before it can be 
moved to long term storage (semantic memory). In HIV, semantic memory is usually well 
preserved or only very mildly impaired, with no temporal gradient such as that typically found 
in Alzheimer’s disease (Grant 2008). If there is difficulty in recalling long term memories, it is 
more likely to be due to problems with search and retrieval, indicating executive dysfunction. 
Thus, in summary, the problem with regards to memory in HAND is with the learning and 
retrieval of new information. 
 
Language is not typically affected by HIV, except for reduced fluency, which is slowed 
generation of words, or speech in general. There may also be poor word choice and 
inappropriate interruptions during conversations (Vally 2011), although these may reflect 
executive dysfunction rather than language dysfunction. This contrasts with cortical 











Motor speed and co-ordination difficulties are often prominent in the later stages of HIV.  
Impairments include bradykinesia, hypomimia, hand tremor and bradyphrenia (Vally 2011). 
They are easily detected through tasks such as the Finger Tapping Test which requires rapid 
movements, or the Grooved Pegboard Test which tests speed as well as fine motor co-
ordination (Grant 2008). 
 
Deficits in executive function are common in HIV. These include difficulties with tasks such as 
abstraction, set shifting, response inhibition and decision making (Grant 2008), which are 
associated with impairment in everyday functioning (Vally 2011). 
 
Earlier studies suggested that visuospatial function is largely unaffected by HIV, however 
newer evidence suggests that there may be subtle impairments (Vally 2011). 
 
Except in cases of frank dementia, the above deficits are often subtle and may vary according 
to the individual. Therefore a structured approach is required to create an overall assessment 
of a person’s neuropsychological function. This is done by testing with a battery of validated 
neuropsychological tests, to cover all the relevant domains, and then through the creation of a 
summary score. The reference standard is considered by most to be clinical ratings by suitably 
trained, experienced neuropsychologists (Carey et al. 2004). A more computational approach 
which is far less labour intensive, is however, usually required. A well validated method is the 
Global Deficit Score approach (Heaton et al. 1995; Carey et al. 2004).  
 
An overall T score is calculated (from the individual’s performance in comparison to the 
demographically adjusted normative values) for each ability domain. This T score is then 
assigned a deficit score, according to the schema devised to by Heaton et al. (1995), which is 
displayed in Table 2.2.  
 
T scores Deficit Score 







Table 2.2: T scores and deficit scores 
 
From: Heaton RK, Grant I, Butters N, White D, Kirson D, Hampton Atkinson J et al. The HNRC 500 – 
Neuropsychology of HIV infection at different disease stages. Journal of the International 












The Global Deficit Score is then calculated by adding the Deficit Scores from each domain, and 
dividing by the total number of added scores. As T scores of 40 or more (which indicate 
performance within normal limits) are assigned a deficit score of 0, whilst T scores in the 
impaired range are assigned progressively higher scores, this method of summarising the 
results from a neuropsychological test battery emphasises poorer performance. This allows for 
the detection of more subtle impairment which may otherwise be lost in simple mean 
calculations across test results.  
 
A cut point (for determination of global impairment) of ≥0.50 has been shown to have very 
good diagnostic power: sensitivity 0.77, specificity 0.92, positive predictive value 0.88, 
negative predictive value of 0.83 and overall diagnostic accuracy rate, as compared to clinical 
ratings by experienced neuropsychologists, of 0.85. The likelihood ratio of detecting 
neuropsychological impairment is 9.38. (Carey et al. 2004). 
 
In the same study by Carey et al. (2004), it was shown that 93% of the participants who had a 
global deficit score of ≥0.50, also had impairment in at least two ability domains as determined 
by clinical ratings (Carey et al. 2004). This is important as the diagnostic criteria for HAND 
require diagnosis of impairment in at least two ability domains (Antinori et al. 2007).  
 
The global deficit score approach has advantages in that it provides a continuous measure of 
impairment as opposed to a categorical measure. It also avoids the need to assess and score 
activities of daily living and related functional impairment, which is always a challenge. 
 
2.2.2.5 Functional Significance 
 
HAND is common, with 30-60% of HIV positive individuals being affected (Grant 2008), and can 
have multiple adverse effects on the patients’ lives, including difficulties with social and 
occupational functioning and potentially medication adherence (Heaton et al. 2004). With the 
success of HAART therapy and now much longer life expectancy for HIV infected persons, 
management of HIV has shifted from palliation to chronic disease management, and quality of 



















Risk for HAD increases with advanced immunosuppression (Childs et al. 1999). This is 
evidenced by the much higher rates of dementia in the pre-HAART era, when CD4+ T cell (CD4) 
counts routinely fell below 200 cells/ul, and most HIV patients reached end stage AIDS. It was 
also recently confirmed in a large 15 year study in Italy looking at HAND prevalence and risk 
factors (Balestra et al. 2011) and in another study in Uganda (Wong et al. 2007). Now, with 
HAART, we have an effective treatment option which can halt disease progression in the 
majority and allow for immune recovery. However, relatively high rates of HAND remain even 
with HAART. It has been shown that the nadir rather the current CD4 count (which may be 
high due to immune recovery on HAART) is important in terms of predicting risk of cognitive 
impairment (Ellis et al. 2011; Balestra et al. 2011). This suggests that the nadir CD4 count 
represents a “legacy event”, at which a critical level of immunosuppression was reached 
causing permanent neural damage (Ellis et al. 2011). This study also showed the converse, that 
HIV positive patients who never experienced low CD4 counts were relatively protected from 
cognitive dysfunction. This suggests that we should be initiating HAART at an earlier stage. 
Although most international (and South African) guidelines currently recommend a CD4 count 
of 350 cells/ul to be the cut-point for HAART initiation, much debate continues as to whether a 
cut-point of CD4 count of 500 cells/ul might not be better. Studies are currently underway to 




It has been suggested that there may be a difference in the neurotoxic potential amongst the 
different viral clades (subtypes). HIV-1 is the viral strain most commonly found globally. It is 
subdivided into 3 classes M (main), O (outlying) and N (new). More than 90% of the global HIV-
1 burden is class M. Class M is then further subdivided into 9 clades, according to viral 
envelope diversity (A-D, F-H, J and K) (Sacktor et al. 2007).  
 
About 50% of the world’s HIV positive population is infected with clade C virus; making it the 
most common subtype worldwide (Gannon et al. 2011). This is probably related to the fact 
that it is the predominant clade in sub-Saharan Africa and parts of Asia, including India and 











America and Australia, and thus most published data for HIV-1 relates to clade B (see figure 
2.4).  
 
This differing neurotoxic potential has been attributed to differences in the viral protein Tat 
amongst the subtypes (Mishra et al. 2008). Clade B was initially thought to be more neurotoxic 
(Rao et al. 2008) and clade C less so, due to a defect in the dicysteine motif in tat in clade C 
virus (Mishra et al. 2008). However this idea has not been supported by clinical studies in India 
(Gupta et al. 2007) and South Africa (Joska et al. 2010b), where rates of HAND in these clade C 
regions have been found to be equivalent to those in Clade B regions.  
 
A study from Uganda (Sacktor et al. 2009) found clade D to cause worse cognitive outcomes 
than clade A. A different study in Uganda (Laeyendecker et al. 2006) and another in Tanzania 
(Vasan et al. 2006) found clade D to be more rapidly progressive in general. More rapid disease 
progression and therefore immunosuppression, would most likely impact on cognitive function 




Figure 2.4:  Global distribution of HIV-1 subtypes (clades) and recombinants 
 
















Differences in host genotype may play a role in increasing susceptibility to HAND. Some studies 
have shown the E4 allele of apolipoprotein E (APOE) to be associated with the severity of 
cognitive impairment in HIV (Corder et al. 1998; Spector et al. 2010), possibly by increasing 
vulnerability to oxidative stress. The APOE E4 allele has been shown to be strongly associated 
with an increased risk for Alzheimer ’s disease (Corder et al. 1993; Saunders et al. 1993; Poirier 
et al. 1993).  However, other studies have not supported the idea that the E4 allele confers 
increased risk of HAD (Joska et al. 2010d; Burt et al. 2008; Dunlop et al. 1997). 
 
Genetic polymorphisms in monocyte chemoattractant protein-1 (MCP-1) or its receptor (CCR2) 
may influence the risk of HAD by altering CNS inflammatory responses (McArthur et al. 2005; 
Singh et al. 2004; Gonzalez et al. 2002). 
 
Polymorphisms of the tumour necrosis factor alpha (TNF-α) promoter gene may also increase 
the risk of HAD by increasing production of the neurotoxic TNF-α in response to inflammatory 




Anaemia has been suggested to be a risk factor for HAD (McArthur et al. 1993), but given that 
in the HIV positive population it tends to occur with the severe weight loss that occurs with 
advancing suppression, it is uncertain whether it can be considered a stand-alone risk factor. 
 
In the developed world there is a high rate of hepatitis C virus (HCV) and HIV co-infection (15-
30%; increasing to 80% in IV drug abusers) (Nath et al. 2008). HCV has been shown to be 
neurotropic and can cause significant neuropsychological impairment (even in the absence of 
liver dysfunction) (Kramer et al. 2002), yet rarely severe enough to cause dementia. Some 
studies have shown an additive effect in terms of cognitive dysfunction in co-infected patients 
(Letendre et al. 2002; Ryan et al. 2004), but other studies have not supported this idea (Clifford 
et al. 2009). The prevalence of HCV infection in South Africa is reported to be very low 
















HIV and substance abuse often occur together, especially in the developed world where 
intravenous drug abuse and sharing of needles is one of the major forms of HIV transmission 
(Nath et al. 2008). It has been shown that HIV positive people who abuse drugs have more 
rapid progression to more severe forms of cognitive dysfunction (Bouwman et al. 1998; Nath 
et al. 2001). Alcohol abuse has also been shown to increase the risk of HAND (De Ronchi et al. 
2002; Joska et al. 2010c). This may be due to the additive effects of neurotoxicity, as well as 
the psychosocial implications of drug abuse, such as poor medication adherence (Nath et al. 
2008). It has also been suggested that intravenous drug abuse increases the risk of cognitive 




Lower level of education has been linked to increased risk of cognitive impairment in HIV in a 
number of studies (Joska et al. 2010b; Balestra et al. 2011). 
 
There has been a dramatic increase in the number of older people living with HIV. This is 
related mostly to longer lifespan due to HAART therapy, but also reflects the fact that older 
people are now more commonly becoming infected with HIV. Older age has been shown to be 
a risk factor for HAND (Balestra et al. 2011; Joska et al. 2010b; Wong et al. 2007; Valcour et al. 
2004). There is evidence to suggest that the ageing brain is more vulnerable to HIV-associated 
neurotoxicity (Gannon et al. 2011; Ernst et al. 2004; Cherner et al. 2004). However, it is still 
uncertain whether the resultant increased capacity for cognitive impairment is due to 
acceleration of the effects of HIV neuropathogenesis, or due to other factors such as the effect 
of HIV on other neurodegenerative processes, or the effect of age-related co-morbidities 
(Gannon et al. 2011). The long term metabolic effects of ART, especially the protease 
inhibitors, may also play a role in cognitive dysfunction, by increasing vascular risk factors and 
probably cerebrovascular disease.  
 
The interplay of HIV and other neurodegenerative conditions has raised much interest. There 
is growing evidence for the accumulation of abnormal proteins in HIV positive brains, including 
hyperphosphorylated tau, amyloid and alpha-synuclein (Valcour et al. 2011a; Gannon et al. 
2011). The accumulation of these proteins is linked to disorders such as Alzheimer’s disease 
and Parkinson’s disease. The HIV protein tat has been implicated in cerebral amyloid 











2.2.3 Management of HAND 
 
2.2.3.1 Screening and diagnosis 
 
It is important to be aware of the possibility of cognitive impairment in all patients seen with 
HIV, especially considering that the early features of HAND may be quite non-specific. 
Forgetfulness, mental slowing, poor concentration, low mood or even just poor medication 
adherence should alert the practitioner that further investigation is required (Rackstraw 2011). 
A thorough psycho-social history is imperative to detect possible dysfunction not otherwise 
mentioned by the patient. This should cover occupation, managing finances, meal preparation 
and driving abilities (Rackstraw 2011). The European AIDS Clinical Society Guidelines 2009 
advise that any cognitive complaint in an HIV positive person should be assessed with a full 
neurological examination, neuropsychological testing, CSF examination and CNS imaging. It 
also advises further investigation for cognitive dysfunction in all patients with a detectable 
plasma viral load, a CD4 count nadir of less than 200 cells/ul, an ARV regimen with limited CNS 
penetration or ongoing depression (Rackstraw 2011). A large proportion of the HIV positive 
people in South Africa fall into these categories, suggesting that we need more stringent 
screening guidelines. 
 
The gold standard for assessing cognitive function remains a full neuropsychological test 
battery, covering multiple domains of function, administered by an experienced 
neuropsychologist (Anthony et al. 2008; Cherner et al. 2007). According to the 
recommendations of the National Institute of Mental Health workgroup in 1990, optimal 
sensitivity requires an extensive battery, taking seven to nine hours to administer.  Ideally this 
battery should include two to four tests per cognitive domain, with the focus on domains 
known to be affected by HIV (Butters et al. 1990). With increased experience in HIV 
neuropsychological testing, more focussed batteries have been devised, usually taking only 
one to two hours to administer. There has also been emphasis on making tests locally 
applicable in terms of language and cultural norms, for optimal results. 
 
Even a focussed neuropsychological test battery is however generally not feasible in most 
settings, especially resource-limited South Africa. Several screening tools have been developed 
to assist in this regard, yet while some have been shown to be valuable in detecting HAD, 











The Mini Mental State Examination (MMSE) is not a good screening tool for HAD, as it focuses 
on detecting cortical rather than sub-cortical deficits (Sacktor et al. 2005).  Its validity as a 
psychometric test is also dependent on educational level and cultural background (Vally 2011). 
 
The HIV Dementia Scale (HDS) was developed by Power et al. in 1995. It consists of 4 subtests 
which examine memory (four word recall), psychomotor speed (timed written alphabet test), 
construction ability (cube copying) and executive function (anti-saccadic error test). It is scored 
out of 16 with a score of 10 or less indicating possible HAD. Used in this way, it has been 
shown to have a sensitivity of 80%, specificity of 91% and a positive predictive value of 78% for 
identifying HAD (Power et al. 1995) as compared to formal neuropsychological assessment for 
HAD.  
 
Many recent studies have looked at the utility of the HDS in detecting the milder forms of 
HAND (Bottiggi et al. 2007; Smith et al. 2003; Simioni et al. 2010). Smith et al. and Bottiggi et 
al. found the tool to be not sensitive enough, except in frank dementia, whilst Simioni et al. 
found that by increasing the cut-off to 14 points out of 16, the detection of HAND as a whole 
can be greatly increased. For HIV positive patients with cognitive complaints and a score of      
≤ 14, Simioni et al. (2010) found that a possible HAND diagnosis can be detected with 
sensitivity of 83%, specificity of 63% and a positive predictive value of 92%. The criticisms of 
the HDS are that it may be unsuitable for patients of non-Western education, and that the 
anti-saccadic error subtest is difficult for non-neurologists to administer (Sacktor et al. 2005). 
 
The International HIV Dementia Scale (IHDS) was developed by Sacktor et al. (2005) as a cross-
cultural test which aimed to address the limitations of the HDS. It emphasises motor function 
and speed. There are three subtests: a four word recall, a timed finger tapping test and a 
timed alternating hand sequence test (based on the Luria Motor Sequence). The test is scored 
out of 12, with a score of ≤ 10 indicating possible HAD, requiring further assessment (Sacktor 
et al. 2005). The screening tool was validated by Sacktor et al. in the United States and in 
Uganda, where they found similar rates of sensitivity (80%) and specificity (55-57%) for 
detecting possible HAD. A study assessing the validity of this tool in South Africa was 
performed by Joska et al. (Joska et al. 2011b), who found it to be less useful overall, with a 
sensitivity of only 45% and a specificity of 79%. 
 
A new screening algorithm has been proposed by Cysique et al. (2010) which utilises non-











mathematical equation to determine risk of neuropsychological impairment (Cysique et al. 
2010). Although shown to have sensitivity of 70% and specificity of 78% for detecting HAD, it is 
unlikely to be a feasible option in the South African public sector in the near future given the 
requirement of a computer for use during the patient consultation. 
 
2.2.3.2 General management approach 
 
The only current effective therapy for HAND is HAART. HAART aims for complete virological 
suppression, which in turn allows for immune recovery. The optimal timing of initiation is still 
under investigation. Earlier initiation to avoid immunosuppression appears beneficial in terms 
of cognitive protection. However, this must be balanced with the fact that HAART is life-long 
therapy that has several potential side-effects, and for which resistance may develop over the 
long term. Most current international guidelines recommend initiation of HAART when the 
CD4 count falls below 350 cells/ul. 
 
Part of the management of HAND also involves optimising the patient’s general condition. Co-
morbidities should be aggressively managed, as should risk factors for cerebrovascular disease. 
Good medication adherence must be encouraged and the patient should engage in physical 
and social activities. 
 
2.2.3.3 HAART: The effect of HAART in HAND 
 
Since the introduction of HAART, clear improvements have been seen in terms of CNS disease. 
Most notably, the incidence of HAD has decreased in the developed world from approximately 
16% to less than 5% of AIDS patients (Heaton et al. 2011; McArthur et al. 1993; Heaton et al. 
2010). A recent systematic review revealed that studies largely agree: HAART induces a 
significant improvement in neurocognitive status, typically within 6 months of treatment 
(Joska et al. 2010a). This does not, however, imply a complete recovery in all cases, and in fact 
incident cases of cognitive dysfunction can arise even whilst on suppressive ARV regimens. 
Unfortunately, high levels of the milder forms of HAND (prevalence approximately 50%) do 













Causes for the continually high rate of HAND are uncertain, yet several theories have been 
proposed.  
 
Irreversible brain injury may occur prior to the introduction of HAART (Heaton et al. 2011). 
According to current local and international guidelines, HAART is initiated only once the CD4 
count falls below 350 cells/ul, unless there are special circumstances (SA DOH 2010, 2011; 
WHO 2010). In most cases this will allow many years of untreated HIV infection.  Additionally, 
recent work looking at the effects of acute HIV infection on the CNS suggests that damage is 
done as early as a few days after initial infection (Ragin et al. 2011; Valcour et al. 2011). 
Optimal management of acute HIV infection is still uncertain, but perhaps early initiation of 
HAART may be warranted (McPhail et al. 2011). 
 
The blood-brain barrier (BBB) is selectively permeable, allowing passage of molecules 
according to factors such as size, protein-binding and lipophilicity. Additionally it has other 
mechanisms such as the P-glycoprotein membrane efflux transporter, which makes it difficult 
for substances to pass into the central nervous system. In this way it restricts the access of 
antiretroviral agents, and also creates a compartment which is quite secluded from the rest of 
the body. 
 
Antiretroviral drugs differ in their ability to cross the BBB, and in some cases this may result in 
inadequate levels for viral suppression. This observation has led to the development of the 
CNS penetration-effectiveness (CPE) ranking system, published initially by Letendre et al. in 
2008 and revised in 2010. This system was devised after extensive pharmacodynamic and 
pharmacokinetic investigations which showed the differing abilities of ARV agents to cross the 
BBB and establish viral suppression in the CSF. According to the ranking system, each agent is 
assigned a score according to its chemical properties, CSF-plasma concentrations and 
effectiveness in achieving CNS HIV control (1 = below average; 2 = average; 3 = above average 
and 4 = much above average).  
 
A regimen score is calculated by the sum of the individual agent scores. A regimen with a total 
score of seven or less is considered to have low penetration within the CNS, whilst a score of 
more than seven is considered to have a high penetration (Letendre et al. 2011). There is 
convincing evidence that this system correctly identifies regimens which will achieve control of 
HIV replication within the CNS, that is, those regimens with higher CPE have been shown to be 











at the correlation between cognitive outcomes and higher CPE regimens, have shown mixed 
results (Tozzi et al. 2009; Rourke et al. 2011; Letendre et al. 2004; Marra et al. 2009). In this 
regard it is important to remember that CSF viral load is not necessarily equivalent to brain 
viral load. Post-mortem studies have shown higher levels of HIV in brain tissue than in the CSF 
of the same patients (Kumar et al. 2007). 
 
This phenomenon of differing CSF concentrations of ARV agents in the CNS compartment 
could also have implications in terms of the development of resistance. Suboptimal 
suppression could allow resistant strains to emerge, which could then continue to cause 
neurotoxicity despite ART, and which could create a risk of systemic reseeding later on (Hult et 
al. 2008). The seclusion of the CNS compartment from systemic immune responses also allows 
for a reservoir of latently infected cells which cannot be targeted by ART and which could act 
as a driver for ongoing neurodegeneration. 
 
Given that the CNS damage associated with HIV infection is largely immune-mediated, HAART 
may simply be inadequate treatment (Heaton et al. 2011). Although the control of ongoing 
viral replication (which HAART targets) is undoubtedly important in stemming the neuro-
inflammatory response to some extent, more focussed anti-inflammatory therapy may be 
required. Unfortunately, to date, studies examining adjunctive therapies have mostly had 
disappointing results (see table 2.3).  
 
HAART itself may have CNS neurotoxic properties, especially considering the well described 
toxic effects on peripheral nerves (Heaton et al. 2011). A magnetic resonance spectroscopy 
study found evidence of brain mitochondrial damage associated with the use of nucleoside 
reverse transcriptase inhibitors such as stavudine and didanosine (Schweinsburg et al. 2005). 
Another basic science study examined the effect of different ARVs (across the differing 
mechanistic classes), on neuronal integrity and function (Liner et al. 2009). Almost all the ARV 
agents induced some degree of neuronal dysfunction.  
 
Additionally, clinical studies have also indicated potential ART neurotoxicity. In an important 
study by Robertson et al., a cohort of 167 patients who were on successful ARV regimens in 
terms of viral suppression and immune recovery (all had CD4 count above 350 cells/ul), had 
their treatment stopped for a period of 96 weeks. There was a statistically significant 
improvement in the mean neuropsychological test scores, indicating an improvement in 











regards to cognitive outcomes and higher CPE regimens, could be related to neurotoxicity of 
the ARVs. Marra et al. (2009) found higher CPE regimens to be associated with poorer 
cognitive outcomes. 
 
Finally, other factors must also be considered, such as the effect of co-morbidities and ageing 
in the now longer-living HIV positive population (Joska et al. 2010a). These factors may be 
important in increasing susceptibility to, or worsening already existing, cognitive dysfunction. 
This longer-living HIV positive population may also be a source for the increased prevalence of 
HAND, even with effective HAART therapy.  
 
2.2.3.4 Other treatment strategies 
 
Methods of circumventing the problem of drug access across the BBB are being investigated, 
which include the use of nanotechnology for the delivery of ART (Nowacek et al. 2009). 
 
Additionally, given the largely immune-driven pathogenesis and the poorer than expected 
cognitive response to HAART, many other treatment approaches are being investigated (see 
table 2.3). Unfortunately none has yet shown strong enough evidence of efficacy (Simioni et al. 
2011). It has been suggested that perhaps this is related to short follow-up time and the lack of 
biomarkers to allow early identification of HIV positive individuals at increased risk of cognitive 
decline, which would allow for more appropriate trial samples (Simioni et al. 2011). 
Additionally, perhaps, a combination of these agents and HAART would have the best result 












Review of neuroprotective agents studied for use in HAND  
Antioxidants 






Initial trial showed significant efficacy in HAND, but effect has not been 
reproduced in larger trials. (Sacktor et al. 2000; Schifitto et al. 2007; Evans et al. 
2007; Schifitto et al. 2009a) 
Anti-apoptotic drugs 
Lithium No clear neuropsychological benefit (Letendre et al. 2006; Schifitto et al. 2009b), 
but an MRS study  showed an improvement in CNS injury (Schifitto et al. 2009b) 
Calcium channel blockers 
Nimodipine No significant cognitive change, but a trend toward cognitive improvement with 
higher doses (Navia et al. 1998) 
CCR5 Antagonist 
Peptide T No significant cognitive benefit, but trend toward improvement in the more 
severely impaired and those with higher CD4 counts (Heseltine et al. 1998) 
PAF antagonist 
Lexipafant No significant cognitive benefit. Suggested trend towards improvement. (Schifitto 
et al. 2002) 
TNF antagonist 
CPI-1189 No cognitive benefit (Clifford et al. 2002) 
NMDA antagonist 
Memantine No cognitive benefit, although potential  neuroprotective effects shown with MRS 
study 
 
Table 2.3:  Review of neuroprotective agents studied for use in HAND 
 
Adapted from Table 2 in: Simioni S, Cavassini M, Annoni J, Hirschel B, Du Pasquier  R. HIV- associated 

















2.3 HAND in South Africa 
 
The majority of the worldwide HIV burden lies within sub-Saharan Africa. The 2010 edition of 
the UNAIDS Report on the global AIDS epidemic states that there are approximately 33.3 
million people living with HIV infection worldwide. Of these, 22.5 million are in sub-Saharan 
Africa (UNAIDS 2010). However the prevalence of HAND in this region is poorly defined due to 
the paucity of studies conducted here, compared with Europe and the United States.  
 
The HIV literature from the developed world may not be applicable in South Africa given the 
difference in viral clades. These different clades (or subtypes) are due to the genetic diversity 
of the HIV-1 virus, mostly secondary to the high error rate of the reverse transcriptase enzyme 
and lack of exonuclease proof reading activity. There are 9 different clades (A-D, G-H, J and K), 
which are found in different parts of the world (Sacktor et al. 2007). Clade B predominates in 
Europe and the US, whereas in sub-Saharan Africa, clade A, D and C are found.  
 
Clade C is the predominant HIV-1 subtype in South Africa. Studies have been done in the Cape 
Town region which show a high proportion of its HIV positive population is infected with HIV-1 
clade C virus (Orrell et al. 2009; van Harmelen 1999). Orrell et al. (2009) in fact found 98% of 
the HIV positive study participants from Cape Town to be infected with clade C virus.  
 
A few studies have been done in distinct Clade C regions, suggesting a high risk for moderate 
to severe HAND (Joska et al. 2010b; Yepthomi et al. 2006; Lawler et al. 2010).  
 
HAART only became readily available within South Africa’s public sector in 2003 (as opposed to 
1996 in the developed world), and access remains poor in some areas. Additionally, until very 
recently, national guidelines only allowed that the majority of patients be started on HAART 
when their CD4 count fell below 200 cells/ul (SA DOH 2010). This is in contrast to the 350 
cells/ul which is advised by the World Health Organisation (WHO) (WHO 2010), and to which 
South African guidelines were amended in August 2011 (SA DOH 2011).  If a diagnosis of HIV-
associated dementia is made, the patient can be classified as WHO Disease Stage IV, and will 
then be considered for HAART regardless of CD4 count (SA DOH 2010). However no provision 
is currently made for the milder forms of HAND. The fact that the South African HAART 











of HAND in our setting, given that more advanced immunosuppression has been related to 
increased risk of HAND (Heaton et al. 2010). 
 
In addition to the heavy burden of HIV disease, South Africa is a resource-poor setting. This 
equates to busy, often under-resourced clinics, where there is minimal time for lengthy patient 
consultations which may be necessary to detect the more subtle forms of HAND. Furthermore, 
we are bound by protocol in the public sector, which means limited scope for individualised 
ARV choices.  
 
Of note, however, is the change in the South African Antiretroviral Guidelines in April 2010. 
This change was largely aimed at discontinuing the use of the agent Stavudine, which has a 
very unsatisfactory side-effect profile. Therefore the first line regimen changed from 
Stavudine, Lamivudine and either Efavirenz or Nevirapine, to Tenofovir, Lamivudine and either 
Efavirenz or Nevirapine. Although this new regimen is largely much better tolerated, it has a 
lower CPE ranking (7 or 8 previously, compared to 6 or 7 currently) which may be significant in 
terms of cognitive outcomes in HIV. Also of interest is that the first line regimen for pregnant 
women, Zidovudine, Lamivudine and Nevirapine, has a CPE ranking of 10. There is a significant 
proportion of South African women using this regimen, as pregnancy is a time when many 
women undergo testing and initiation of ART, if necessary, as part of the National Prevention 
of Mother-to-Child Transmission (PMTCT) Programme. The regimen would then be continued 
after pregnancy unless unacceptable side-effects or treatment failure necessitated a change. 
 
Further research on HAND in South Africa is needed to determine our unique disease profile 
and response to HAART therapy, as well as our greater management needs. Clinically useful 
biomarkers with the ability to identify patients with increased risk of cognitive decline are also 
urgently needed, and could provide evidence to support a HAART protocol change which 
would cater for patients with the milder forms of HAND. Additionally, further research into the 
CPE implications of our local regimens could provide evidence necessary for considering 



















At a theoretical level, a biomarker (biological marker) is an indicator of a biological state. Most 
often the interest in biomarkers lies in the potential for diagnostic or predictive value. They 
offer the possibility for an objective measure in a condition which may otherwise be a purely 
clinical diagnosis.  They could also be used to identify people at increased risk for a given 
condition, which could allow for more focussed and possibly earlier treatment for these 
people. This ability would also allow for the optimal choice of participants for clinical trial 
populations for potential new therapies. 
 
Biomarkers could really be any measurable entity relating to a biological state; however 
chemical and radiological biomarkers are generally most studied.  
 
Chemical markers are substances found in body fluids. In HAND, that would usually be either 
blood or cerebrospinal fluid (CSF). CSF probably offers a closer reflection of what is occurring in 
brain tissue, yet requires a much more invasive procedure to acquire. Alternatively, blood is 
more accessible and is far more frequently sampled. Given that HIV is a multisystem disease, 
and that the pathogenesis of HAND is linked to systemic immune function, examining 
substances in the peripheral circulation can still be extremely informative in terms of HAND. I 
therefore believe that the investigation of serum markers deserves further attention. 
 
The two main biomarkers of HIV disease already thoroughly incorporated into clinical practice 
are the HIV RNA level which indicates the viral load in the measured body fluid, and the CD4+ T 
lymphocyte count, which gives an indication of immunodeficiency (Mildvan et al. 2005). 
Further potential biomarkers are being investigated.  
 
There has been much recent work in the developed world around biomarkers of HIV CNS 
disease in particular, which could help with the identification and categorisation of HAND 
(McArthur et al. 2005). It is hoped that biomarkers might be able to help not only with 
diagnosis and prediction of prognosis of HAND, but also be able to assist in management 











disease, and to assist with choosing optimal ARV regimens and in the assessment of response 
to treatment (Brew et al. 2009).  
 
The biomarkers under investigation are largely drawn from three important areas in the 
pathogenesis of HAND, namely viral markers, markers of immune activation and markers of 
neurodegeneration. Most work has been done on cerebrospinal fluid. However, there are also 
important markers which can be measured in the peripheral blood.  
 
2.4.2 Viral biomarkers 
 
Viral markers include HIV RNA, HIV DNA and specific viral proteins. HIV DNA is created through 
the reverse transcription of viral RNA, and is then incorporated into the host cell genome. 
Plasma levels (measured from peripheral monocytes) therefore reflect latent infection. A 
correlation with HAND has been proposed, as levels were found to be increased in patients 
with clinical features of HAND (Shiramizu et al. 2005; Shiramizu et al. 2007). A correlation was 
also found between the level of HIV DNA in monocytes and cognitive function, in a group of 
patients prior to ART initiation and after 48 weeks on treatment (Valcour et al. 2009). 
 
2.4.3 Immunological biomarkers 
 
The markers of immune activation that have been most studied are neopterin, beta-2-
microglobulin, quinolinic acid and monocyte chemotactic protein 1 (MCP1/CCL2) (Price et al. 




Neopterin is a product of guanosine triphosphate metabolism, which is produced by 
macrophages which have been stimulated by interferon gamma. It can therefore be 
considered as a marker for cellular immune activation (Huber et al. 1984). It is found in human 
body fluids during times of cellular immune responses, for example during viral, bacterial and 
parasitic infections, and with autoimmune disease, malignancy and allograft rejection 
(Wirleitner et al. 2005). 
 
Neopterin levels are raised in the body fluids of HIV positive individuals throughout the course 











measurable antibody production. (For this reason, neopterin levels are used in blood and 
organ donation screening.) In the early asymptomatic phases the levels are low, but remain 
above normal in about 80% of HIV positive individuals, and rise gradually with the progression 




Figure 2.5: Schematic diagram of the course of neopterin development over time in HIV positive 
patients. 
 
From: Wirleitner B, Schroeksnadel K, Winkler C, Fuchs D. Neopterin in HIV-1 Infection. Molecular 
Immunology 2005; 42: 183-194. 
 
Neopterin has been shown to have a significantly inverse correlation with CD4+/CD8+ T cell 
ratios and absolute T cell numbers (Fuchs et al. 1988). Neopterin is able to discriminate the 
different clinical stages of HIV infection as well as CD4 count (Hutterer et al. 1987). Neopterin 
levels in the serum and urine have therefore been shown to be useful markers in the course 
and progression of HIV disease in general (Hagberg et al. 2010; Kitchen et al. 2008; Mildvan et 
al. 2005). Neopterin is able to pass though the BBB and serum levels usually have a linear 
relationship to CSF levels (Andersson et al. 2001). 
 
Higher neopterin levels have been demonstrated in the CSF of patients with HIV-associated 
cognitive impairment, as compared to neurologically asymptomatic patients (Fuchs et al. 1989; 
Brew et al. 1990; Hagberg et al. 2010). These levels were also shown to have a correlation with 
cognitive function, in that higher levels were found in the more impaired patients when 
compared to the minimally impaired patients (Hagberg et al. 2010). Neopterin levels 
decreased in response to ART, yet remained elevated above normal level (Hagberg et al. 2010; 
Hagberg et al. 2004). Blood levels of neopterin were also found to be higher in the cognitively 











higher than 200 cells/ul), but to a lesser extent than in the CSF, indicating intrathecal immune 




Osteopontin is a soluble protein found in most body fluids. It is produced by a variety of cells, 
including macrophages. As its name suggests, it was originally identified as a substance found 
in bone. It forms part of the bone matrix and assists with the regulation of mineralization. It 
was subsequently also discovered to be a pro-inflammatory cytokine with immune modulating 
effects (O’Regan et al. 2000; Wang et al. 2008). It can therefore be seen as an inflammatory 
marker.  
 
Osteopontin was shown to have a potentially important role in the pathogenesis of HAND, 
through its effects on monocytes, in a study by Burdo et al. (2007). These researchers used in 
vitro models to examine the effects of osteopontin on human monocytes. One model 
consisted of a simulated BBB made of endothelial cells grown on a collagen gel. Although it 
was not found to have classic chemotactic effects for monocytes, it was shown that 
osteopontin has retention effects on monocytes (especially the CD14+/CD16+ variety). When 
applied to the human context, this means that osteopontin can prevent reverse transmigration 
over the BBB and out of the CNS (Burdo et al. 2007). Osteopontin was also shown to protect 
these monocytes from apoptosis (Burdo et al. 2007). Given that the monocyte/macrophages 
are the principal cell types for HIV replication in the CNS, and are important in mediating the 
resultant neurotoxic inflammatory cascade, these effects which ultimately increase the 
monocyte/macrophage population within the CNS must have an important role in the 
development of HAND (Burdo et al. 2007). 
 
Burdo et al. also showed that plasma osteopontin levels were raised in monkeys with Simian 
immunodeficiency virus encephalitis, as compared to control Simian immunodeficiency virus 
monkeys without encephalitis (Burdo et al. 2007).  
 
Osteopontin was recently also shown to be raised in the plasma of HIV positive human 
individuals, with minimal decrease with HAART (Chagan-Yasutan et al. 2009). Furthermore, 
plasma levels of osteopontin were shown to be significantly increased in patients with HIV 
dementia, and a significant correlation was shown between plasma osteopontin levels and HIV 











The monkey component of the study also had a longitudinal arm looking at plasma 
osteopontin levels in relation to the development of simian AIDS and encephalitis. Here it was 
found that the plasma osteopontin levels increased before the onset of neurological 
abnormalities (Burdo et al. 2008), suggesting a possible predictive role for the substance.  
 
Another study showed that osteopontin can stimulate HIV-1 replication (through activation of 
the nuclear factor kappa B (NFĸB) pathway), and further confirmed that high levels of 
osteopontin, this time in cerebrospinal fluid, remained even with HAART (Brown et al. 2011).  
 
2.4.3.3 C-Reactive Protein (highly sensitive) 
 
The SMART study, which looked primarily at the effects of episodic versus continuous 
antiretroviral therapy, also included a sub-study on biomarkers. One of the studied substances 
was C-reactive protein (CRP), a systemic pro-inflammatory marker, which was shown to be 
associated with mortality risk in HIV positive patients (Kuller et al. 2008).  Two recent studies 
have shown a correlation between elevated serum CRP and cognitive decline in elderly HIV 
negative patients (Hoth et al. 2008; Komulainen et al. 2007). The relationship of serum CRP to 
HAND has not been investigated (Wright et al. 2009). 
 
2.4.4 Neurodegenerative biomarkers 
 
Markers of neurodegeneration include neurofilament protein, tau and S100 beta (Morris et al. 
2010). 
 
2.4.4.1 Neurofilament protein 
 
Neurofilament (NF) protein is a major structural element of neurons, especially the large 
myelinated variety, where it is involved in the maintenance of axonal integrity. It is released 
not only from dying, but also dysfunctioning neurons (Petzold 2005). It has three subunits – 
light (L), intermediate (I) and heavy (H).  
 
The light subunit has been well studied in the CSF, where it has been shown to be a sensitive 
biomarker of axonal damage, both for acute conditions as well as for various 
neurodegenerative diseases (Mellgren et al. 2007; Rosen et al. 2004; Rosengren et al. 1999) 











HAART, as well as to rise with HAART interruption (Abdulle et al. 2007; Gisslen et al. 2005; 
Mellgren et al. 2007). Another study found CSF NFL to have predictive qualities for the 
development of HAD (Gisslen et al. 2007).  
 
Neurofilament heavy chain (NFH) is highly phosphorylated and is therefore more stable than 
NFL, and much more resistant to proteases. This means it can be measured in the peripheral 
blood (Petzold 2005). Plasma NFH has been shown to be a marker of neuronal injury in 
multiple sclerosis (Gresle et al. 2011) as well as other neurodegenerative conditions, like 
Alzheimer’s disease and Vascular Dementia (Petzold 2005).  
 
NFH has also been studied in HIV infection. Anderson et al. examined NFH levels in the CSF of 
HIV positive individuals, as well as the CSF of individuals with multiple sclerosis and other 
neurological disorders (Anderson et al. 2011). NFH levels were shown to be significantly higher 
in HIV disease than in other neurological diseases. However the levels within HIV disease did 
not relate specifically to the level of cognitive function, with raised CSF levels found even in 
cognitively normal patients (Anderson et al. 2011). This is important as it shows that 
detectable CNS neurodegeneration is occurring before the onset of neurological symptoms.  
Another interesting finding in this study pointing to the possible utility of NFH as a biomarker 
for HAND, was that on serial CSF determination, those who deteriorated cognitively also had 
an associated increase in their CSF NFH levels (Anderson et al. 2011). No correlation was found 




Tau is a microtubule-associated protein, found in the axons of CNS neurons, where it has 
important structural functions, as well as being involved in axoplasmic flow. It is released 
extracellularly after CNS injury. It can therefore be seen as a marker of axonal CNS damage 
(Kavalci et al. 2007; Ramlawi et al. 2006). Two main types can be measured: total tau and 
phosphorylated tau. Both reflect neuronal damage non-specifically. Both forms have been 
shown to be elevated in the CSF of neurologically symptomatic HIV patients (Brew et al. 2005).  
 
Tau has also been successfully assayed in serum, and correlated to CNS injury following head 
injury and stroke (Shaw et al. 2002; Bitsch et al. 2002). Another study correlated increased 











2006). Interestingly, this study also showed increased CRP and inflammatory cytokines to be 
associated with neurocognitive decline (Ramlawi et al. 2006).  
 
2.4.4.3 S-100 beta 
 
S-100 is an acidic calcium-binding protein which is found in dimer forms with alpha and beta 
subunits (Brew et al. 2008). S-100 beta (S-100β) is found almost exclusively in astrocytes 
(Pemberton et al. 2001). It has been shown to be a marker of astrocytosis (Pemberton et al. 
2001) and raised levels are found in a number of inflammatory, degenerative and traumatic 
CNS conditions (Lamers et al. 2003), making it a useful biomarker for brain injury (Chaves et al. 
2010). More specifically, raised CSF S-100β has been shown to be associated with increased 
HAND severity and a quicker decline to HAD (Pemberton et al. 2001).  S-100β can be measured 
in the CSF as well as the blood (Lamers et al. 2003). A recent study examined serum S-100β 
levels in Alzheimer’s disease, and found a positive correlation between these levels and the 
severity of dementia (Chaves et al. 2010). S-100β has a short half-life, therefore constantly 
elevated levels indicate continuous release from damaged tissue, making it a worthwhile 
marker of ongoing neurodegeneration (Stroick et al. 2006). 
 
Most HAND biomarker research has focussed on single markers, either in the CSF or blood, but 
no one marker has yet been shown to fulfil one or more of the desired functions with sufficient 
sensitivity and specificity. It has been suggested that investigating the different types of 











Chapter 3 – Aims and hypotheses 
 
This study had two main aims: 
 
Firstly, to determine whether HAART improved cognitive function in HIV positive patients in 
South Africa, and more specifically whether this effect differed according to the CNS 
penetration-effectiveness of the antiretroviral regimen used.  
 
Secondly, to determine whether the proposed inflammatory and neurodegenerative 
biomarkers related to the severity of cognitive impairment at baseline in HAART-naïve 
patients, and whether initial levels of these biomarkers could be correlated with the change in 
cognitive function a year later. 
 
In order to address these aims, specific hypotheses were drafted. 
 
Hypothesis one: HAART of at least ten months will im rove cognitive function in HIV positive 
ARV-naïve patients with a CD4 count of less than 350 cells/ul and cognitive dysfunction at 
baseline. That is, participants with impaired cognitive function at baseline, as assessed using a 
battery of neuropsychological tests to derive a global deficit score, will show improvement one 
year later, after at least ten months of HAART therapy; while participants with impaired 
cognitive function at baseline, and a CD4 count less than 350 cells/ul, who have not been on 
HAART therapy will not show improvement one year later. 
 
It was stipulated that all study participants analysed to test this hypothesis, should have a CD4 
count of less than 350 cells/ul. This was necessary for an accurate comparison to determine 
the effects of HAART, as otherwise differing levels of immunosuppression (as reflected by the 
CD4 count) would have been a confounding factor in this analysis. 
 
Of note, HAART was not purposefully withheld from any study participants.  Reasons for the 
participants with a CD4 count of less than 350 cells/ul not to have received HAART included 
the change in the national HAART initiation threshold during the study period, and in some 
instances, failure of HAART initiation, despite eligibility, at the ART clinics. The reasons for the 











this study, it was apparent at the time of the hypothesis drafting that such a group existed for 
further analysis.  
 
At least ten months of HAART therapy was chosen as the cut-off point for the HAART analysis, 
as the follow-up assessment of cognitive function was done after twelve months. This was to 
ensure that the baseline assessment was a true pre-HAART assessment of the participants, 
when they were theoretically at their worst in terms of immunosuppression and the effects of 
untreated HIV disease. As the follow-up period was not adjustable, if a shorter treatment 
duration cut-off time had been chosen, for example six months, there might have been a 
longer period between the baseline cognitive assessment and initiation of HAART. This would 
have allowed for a further period of decline in cognitive function and CD4 count, meaning that 
the baseline would not have been a true baseline.  
 
Hypothesis two: HAART is protective of cognitive function; that is, HIV positive patients with 
normal cognitive function at baseline who then use HAART for at least 10 months, will still 
have normal cognitive function at the one year follow-up visit, as opposed to HIV positive 
patients with normal cognitive function at baseline who do not receive HAART. 
 
Hypothesis three: HAART regimens with greater CNS penetration-effectiveness (regimen CPE 
more than seven) will be more effective in improving cognitive outcomes in HIV positive 
patients, compared with HAART regimens with a lower CNS penetration-effectiveness 
(regimen CPE seven or less); such that patients on HAART regimens with a CPE of more than 
seven will have greater cognitive improvement at the one year follow-up visit, than those on 
regimens with a CPE of less than or equal to seven. 
 
The categorisation of the CPE regimen scores into “low” and “high” was done according to the 
scheme devised by Letendre et al. (2010; 2011) (see section 2.2.3.3, p22). A regimen score is 
calculated by the sum of the individual agent scores. A regimen with a total score of seven or 
less is considered to have poor effect in the CNS, whilst a score of more than seven is 
considered optimal in terms of achieving HIV viral suppression within the CNS (Letendre et al. 
2010; 2011). 
 
Examination of the cognitive effects of high versus low CPE regimens had become clinically 
relevant, given the change in the South African National Antiretroviral Therapy guidelines in 











Hypothesis four: Serum levels of the inflammatory markers neopterin, osteopontin and the 
neurodegenerative marker neurofilament H protein, will be significantly different in the HIV 
positive group as compared to the HIV negative control groups. 
 
Three different control groups needed to be included in this study: Firstly, HIV negative 
participants, drawn from the same demographic areas as the HIV positive study subjects, and 
according to the same inclusion and exclusion criteria (except for HIV status). This was 
required to compare the effect of HIV on the biomarker levels.  
 
Secondly, a group of HIV negative participants with another neurodegenerative disorder 
causing cognitive impairment, to compare the biomarker profile of HAND to this other 
disorder. As there was an Alzheimer’s disease (AD) study being conducted by other members 
of my research group and for which I was involved with patient assessments, this was an 
obvious choice. However, given the very different demographic settings of the HAND and the 
AD studies, a third group of HIV negative participants was required, as demographically similar 
controls to the AD participants. 
 
With the above groups it was possible to observe the effect of both HIV infection and cognitive 
dysfunction on the biomarker levels.  
 
Unfortunately only three potential biomarkers could be tested due to practical constraints 
(limited stored serum volumes) and financial restrictions. 
 
Ethical permission was not granted for CSF sampling, and therefore the chemicals had to be 
examined within the serum. 
 
Hypothesis five: Serum levels of the inflammatory markers neopterin, osteopontin and the 
neurodegenerative marker neurofilament H protein, will relate to cognitive function in HIV 
positive individuals. That is, highest levels will be measured in HIV positive patients with severe 
cognitive impairment, lower levels in mild to moderate impairment, and even lower levels in 
HIV positive patients with normal cognition. 
 
This was an important hypothesis for examining the ability of the selected chemicals to 











Given the current understanding of HAND pathogenesis, as an entity caused largely by 
neurodegeneration secondary to the inflammatory cascade initiated by HIV in the CNS, it 
seemed likely that markers of inflammation and neurodegeneration would correlate with 
clinical disease severity. 
 
Hypothesis six: Higher initial serum levels of the proposed inflammatory and 
neurodegenerative markers will be associated with a change in cognitive function (as 
measured by the change in global deficit score) after approximately one year; such that higher 
initial marker levels will be associated with greater cognitive improvement one year later, after 
at least ten months on HAART, but in those patients not on HAART, higher initial serum levels 
of the markers will be associated with a decline in cognitive function at the one year follow-up 
visit. 
 
Once again, given the currently understood pathogenesis of HAND, it seemed likely that higher 
initial levels of the markers would be associated with a decline in cognitive function without 
HAART; that is, as the natural disease progression would occur. However, with HAART, there 
would be viral control, and therefore potential suppression of the inflammatory response. In 
theory, this would lead to clinical improvement. It was hypothesised that the potential for 
improvement would be greatest in those with higher levels of inflammation and neuronal 
damage at baseline. 
 
Hypothesis seven: Higher initial serum levels of the proposed inflammatory and 
neurodegenerative markers will be associated with the change in cognitive function according 
to the CNS penetration-effectiveness of the HAART regimen used; that is, participants with 
higher initial serum levels of the proposed inflammatory and neurodegenerative markers will 
have greater improvement in cognition if they are on HAART regimens with a CPE of more than 
seven, as opposed to regimens with a CPE of less than or equal to seven. 
 
Similar logic was followed here as in hypothesis six, except that in hypothesis seven,  the effect 
of the high and low CPE categories was being examined. It was hypothesised that with 
increased blood-brain barrier penetration, those HAART regimens of high CPE ranking would 
be more effective in dampening the inflammatory response and reducing the resulting 
neuronal damage. Once again, it was assumed that this effect would be greatest in those with 












Chapter 4 – Methods 
 
4.1 Introduction and overview of methods 
 
This project formed part of a collaborative research programme into HIV-Associated 
Neurocognitive Disorders in the Western Cape, by the Departments of Psychiatry and 
Neurology, at the University of Cape Town. A large database of patient information had 
already been, and continued to be, collected. Additionally, frozen serum samples had been 
stored at   -80°C for further investigations.    
 
Participants for this study were recruited randomly from three primary level ARV clinics in the 
Cape Town area from the beginning of 2008 until mid 2010. These participants were all at the 
stage of counselling and preparation for beginning HAART therapy. Demographically similar 
HIV negative control patients were recruited from HIV testing centres at the same clinics. 
 
At baseline, the participants completed various questionnaires, a neuropsychological test 
battery (specifically designed to identify cognitive deficits often found in HAND), a full 
neurological examination and had blood taken for investigations. The nadir CD4 count was 
recorded for each patient.   Magnetic Resonance Imaging scans were also performed.  
 
After one year, the patients were followed up with repeat testing and examination, as well as 
documentation of their ARV therapy details. 
 
This component of the larger study involved a retrospective review of previously collected 
patient clinical information, as well as the arrangement for the reassessment of some of the 
participants, and the performance of new laboratory investigations.  
 
Data from two different cohorts of patients were used. The first cohort was recruited from the 
beginning of 2008 and completed follow-up by mid 2010. The second cohort was recruited 
from the same clinics from August 2009, and assessed at baseline (pre-HAART) in a very similar 
way to the first cohort. However, these participants form part of a different study by the GSH 
HIV Mental Health Group, which is cross-sectional in nature and therefore does not include 











arranged, with selection according to when the participants were initially seen, to allow for the 
one year reassessment to fall within the second half of 2011. 
 
The first part of this study was cross-sectional. It looked at levels of a few selected serum 
biomarkers in HIV positive participants, as well as in HIV negative control participants. Both 
groups include cognitively normal and cognitively impaired participants. The biomarkers which 
were identified for further research in this study are the inflammatory markers (neopterin and 
osteopontin) and the neurodegenerative marker neurofilament heavy chain protein (NFH). 
Unfortunately only a few markers could be investigated due to practical constraints (limited 
stored serum sample volumes) and financial limitations. 
 
The second part of the study was longitudinal. Biomarker levels were measured on the stored 
baseline, pre-HAART blood samples, using commercially available assays. These levels were 
then related to the cognitive status of the participants at baseline, and to the cognitive status 
one year later. In some participants this meant after a year of HAART therapy, whilst others 
remained HAART-naïve.  
 
Additionally, correlates between change in cognitive function and the CNS penetration-
effectiveness of the specific ARV regimen used were investigated. This was the main reason for 
including the second cohort of participants who were recruited later, as they would have been 
initiated on the new South African first-line HAART regimen, as opposed to the first cohort 
which started the old first-line regimen, allowing for a review of the effect of the CPE 
differences. 
 
4.2 Study Design 
 
The design had two main components: 
 
Firstly, a cross-sectional analysis of biomarker levels and their correlation with HIV status, and 
cognitive dysfunction.  
 
Secondly, a longitudinal investigation into the change in cognitive function of HIV positive 
participants over a period of approximately one year, and the relationship of this change to 












4.3 Sample Size 
 
This project made use of available stored serum samples and clinical data. Whilst new clinical 
information was collected from the second cohort of HIV positive participants, there was not 
much scope to increase the sample size, as there was the limitation of the number of 
participants who had been assessed at baseline, within the required time period. Overall, 125 
HIV positive participants were included in the study. 
 
The numbers included in the two main sections of the study were equivalent to similar studies 
conducted recently. A systematic review, which examined fifteen studies looking at the effect 
of HAART on cognitive function, reported that sample sizes within these studies ranged from 
14 to 126 participants (Joska et al. 2010a).  Sample sizes in recent biomarker studies that 
yielded significant results were: for NFH, n = 76 (Anderson et al. 2011), for osteopontin, n = 95 
(Burdo et al. 2008), and for serum neopterin, n = 110 (Anderss n et al. 2001) and n = 152 
(Mildvan et al. 2005). 
 
A post hoc power analysis was done in consultation with a statistician, for the primary 
outcome of neuropsychological response to HAART after one year. The power to detect a 0.25 
difference in GDS between the two group means, with a sample size of 125, alpha 0.05, for a 
preHAART mean GDS of 0.8 and a standard deviation of 0.6, was 90.89%. 
 
4.4 Recruitment of participants 
 
HIV positive participants for this study were recruited from three primary level ARV clinics in 
the Cape Town area, namely Nolungile Clinic in Site C Khayelitsha, Woodstock Community 
Health Centre and Mitchells Plain Community Health Centre. Staff at the clinics assisted in the 
recruitment of participants. Patient folders were drawn at random on a particular day, to be 
approached and screened for possible inclusion in the study. If these patients signed informed 
consent and were found to meet the criteria, study visits were scheduled at Groote Schuur 
Hospital.  
 
Demographically similar HIV negative control patients were recruited from HIV testing centres 
at the same clinics. The counsellors at these centres assisted with the recruitment. After the 
voluntary counselling and testing process was complete, if the patient had a negative result, 











Another small group of HIV negative participants with cognitive dysfunction due to probable 
Alzheimer’s disease (AD) was included in the study as positive controls for the biomarker 
analysis. These participants were recruited as part of another study by the Division of 
Neurology, Groote Schuur Hospital, which is investigating Alzheimer’s disease. These patients 
were all older than 60 years and met NINCDS/ADRDA criteria for probable Alzheimer’s disease 
(McKhann et al. 1984; Dubois et al. 2007). They were recruited from Groote Schuur Hospital 
outpatient clinics (primarily the Division of Geriatric Medicine’s Memory Clinic), private 
medical practices and old age homes in the Cape Town area. These participants underwent a 
full neurological examination, cognitive assessment and routine blood tests. Some participants 
underwent computerised tomography (CT) scanning for diagnostic clarification. In addition, 
the participants had given consent for their blood samples to be stored and used for further 
research investigations. 
 
4.4.1 Inclusion criteria for the HAND study 
 
The following criteria needed to be met for inclusion in the study: 
• Participants had to sign informed consent.  
• Participants needed to be between 18-35 years (to exclude age-related confounding 
factors).  
• Participants needed to have completed formal schooling up to Grade Seven. 
 
The HIV positive participants  
• Had to have attended the clinic at least once prior to the visit on which they were 
approached. 
• Had to have been diagnosed with HIV infection within the last six months. 
• Had to be at the stage of counselling and preparation for beginning HAART therapy.   
 
4.4.2 Exclusion criteria for the HAND study 
 
Participants were excluded if they were found to have one or more of the following: 
• Uncontrolled medical conditions 
• Significant psychiatric or CNS diseases  
• Substance or alcohol abuse (within the last three months)  
• Previous moderate-severe head injury (loss of consciousness for more than 30 minutes 












Screening questionnaires were used to assist with identifying inclusion and exclusion criteria, 
as well as for collecting demographic information.  (Beck Depression Inventory, The Alcohol 
Use Disorders Inventory, Substance Abuse and Mental illness Screener, Life Events 
Questionnaire of Brugha, The Childhood Trauma Questionnaire, Patient’s Assessment of Own 




The larger HAND research project had been approved by the Human Research Ethics 
Committee of the Faculty of Health Sciences at the University of Cape Town (REC 263/2007) 
(amendment 19 May 2008) and (REC 203/2008). An additional amendment for the specific 
new analyses included in this study was also approved (amendment 28 July 2011). The greater 
Alzheimer’s disease research project, from which some of the control patients were drawn, 
also had full ethics approval (REC 270/2007). 
 
4.6 Assessment of participants 
 
Clinical assessments were conducted at Groote Schuur Hospital in the Psychiatry Outpatients 
Department. MRI scans were performed at the Cape Universities Brain Imaging Centre (CUBIC) 
at Tygerberg Hospital.  
 
At baseline, all HIV positive participants completed a medical assessment and a 
neuropsychological test battery, had an MRI scan and had blood taken for investigations. At 
the follow-up visit approximately one year later, the neuropsychological assessments were 
repeated, and some participants had repeat medical assessments. Additionally information 
regarding the participants’ HAART therapy was collected. This included the duration of therapy 
as well as the particular agents used. 
   
The demographically similar HIV negative control participants only attended the baseline visit, 
and only completed the neuropsychological test battery. A small sub-group (10) was selected 












The Alzheimer’s disease control patients had blood samples taken at their baseline visits as 
part of their Alzheimer’s disease research assessments. Some of these blood samples were 




4.6.1.1 General evaluation 
 
All participants completed some general evaluations as well as the focussed medical and 
psychological assessments. The following tests were performed: socio-demographic 
questionnaire, Miniature International Neuropsychiatric Interview plus, International HIV 
Dementia Rating Scale, The Neuropsychiatric Inventory, Cape Town HIV Consortium risk 
behaviour scale, Karnofsky Performance Scale, Camberwell Assessment of Need and the 
Sheehan Disability Scale. 
 
4.6.1.2 Neurological evaluation 
 
HIV positive participants underwent a medical assessment, according to a scheme devised by 
the study team. This assessment had a focussed history to detect neurological difficulties, and 
then an examination to detect signs of peripheral neuropathy as well as abnormalities of the 
motor system (tone and power changes), co-ordination, involuntary movements, primitive 
reflexes and a timed gait test. 
 
4.6.1.3 Neuropsychological evaluation 
 
The neuropsychological test battery was chosen by the Groote Schuur Hospital Department of 
Psychiatry, to test domains known to be commonly affected by HIV infection. It was based on 
the battery used by the HIV Neurobehavioural Research Center, at the University of California. 
The aim was to use similar tests to that used internationally, to allow for comparison of results. 
However the tests also needed to be locally suitable and to this end three local 
neuropsychologists were consulted. Small changes were made, such as substituting words in 
the word lists, and idioms, to make the tests more locally suitable. All the material for the tests 
was also translated into isiXhosa, which is the first language of the majority of the participants. 













Tests according to 
Domain 
 
What the test entails 
Motor skills 
Grooved Pegboard Test 
(Klove 1963) 
Timed test in which pegs (with both a round and a flat side) 
must be inserted into slots within a wooden board, making it a 
test of manual dexterity, fine motor coordination and motor 
speed; performed with the dominant and non-dominant hand. 
Finger Tapping Test Test in which the tip of the thumb must be tapped against the 
tip of each other finger on the hand in sequence. This task is 
timed and must be performed five times, with the dominant 
and non-dominant hand in turn. 
Memory (learning, recall) 
The Hopkins Verbal Learning 
Test (HVLT) 
(Brandt 1991) 
A list of words is read to the participant. These words must be 
immediately repeated (three trials are allowed, with a 
rereading of the list in between). This creates the learning 
score. The words must then be recalled after 15 minutes, and 
also be recognised from a longer list of words with other 
similar distracter words. These tasks create the recall score.   




Participants view 6 geometric figures laid out in a 2x3 array on 
a page for 10 seconds. They must then reproduce this as 
closely as possible from memory. Three learning attempts are 
required. 25 minutes later the test is repeated. At this stage 
the participants are also requested to identify the 6 figures 
from a list of 12 similar figures.  
The Rey Osterrieth Complex 
Figure (RCF) 
(Corwin et al. 1993) 
Participants are required to reproduce a complicated line 
drawing, first by copying from the given image, and then later 
















Psychomotor processing speed 
Trail Making Test A (TMTA) 
(Reitan 1958) 
Timed test in which circled numbers must be connected in 
ascending sequence. 
Color Trail Making I  
(D’Elia et al. 1996) 
Timed test in which circled numbers must be connected in 
ascending sequence. (The colour of the circled numbers 
alternates as the numbers ascend, but there is only one of 
each number.) 
Wechsler Adult Intelligence 
Scale, 3
rd
 Edition - WAIS III  




In digit symbol coding, the participant is presented with digit-
symbol pairs. They are then subsequently required to write the 
appropriate symbol next to a list of digits, as quickly as 
possible. 
Symbol search requires correctly identifying given symbols 
from a list of similar symbols, under time pressure. 
Attention (and working memory) 
Wechsler Memory Scale III 
(Mental Control) 
(Wechsler 1997b) 
The participants are required to recite known sequences, such 
as numbers from 1-20, the alphabet, days of the week and 
months of the ye r.  With the exception of the alphabet, these 
tasks are then repeated in reverse (i.e. counting 20-1, days’ 
order backwards etc). Finally the participant needs to say the 
days of the week sequentially, alternating each day with an 
increasing multiple of 6 (i.e. 0 Sunday, 6 Monday, 12 TueSDay 
etc). All these tasks are done under time pressure. 
Mental Alternation Test  (MAT) 
(Jones et al. 1993) 
Participants initially count to twenty, then recite the alphabet, 
then do both at the same time, alternating numbers and 
letters in ascending sequence. This is done under time 
pressure. 
Executive Function 




In this task, the participant is asked to recognise colours, then 
read the names of colours in black and white print, before 
being shown a sheet with the names of colours, printed in 
another colour (e.g. RED written in blue ink). Here, they are 
required to say the colour that they see and not read the word 












Color Trail Making II 
(D’Elia et al. 1996) 
Timed test in which circled numbers must be connected in 
ascending sequence, alternating between two different 
colours of circle. (The correct colour must be chosen each time 
– each number appears in both colours.) 
Wisconsin Card Sorting Test 
(WCST) 
(Heaton 1993) 
Stimulus cards are presented to the participant with differing 
shapes of different colours and quantities printed on them. 
The participant is then given another set of cards to “match” to 
the stimulus cards. The tester decides how the cards are to be 
matched, i.e. according to shape, colour or quantity. The 
participant is not told how to match the cards, but is instructed 
when they have made a correct or incorrect match. The 
criteria for matching are altered throughout the test, meaning 
the participant needs to keep finding the new pattern. 
Wechsler Adult Intelligence 
Scale, 3
rd
 Edition - WAIS III  




The block design and matrix reasoning subtests were 
performed. In block design the participant is given four 3-
dimensional blocks with different prints on each face. They are 
then shown a geometric pattern which must be created by 
correct placement of the blocks next to each other (by 
choosing the appropriate face to display). This response is 
timed. In matrix reasoning, the participants are shown a 
pattern of 3 blocks, they must then choose the best fit block to 
complete the design from a selection of 4 possibilities. 
Verbal Fluency (and executive functioning) 
Category Fluency Test (Animals 
& Fruit/Vegetables) 
(Spreen et al. 1998) 
Participants must name as many animals (or fruits and 
vegetables) as possible within one minute. 
 






















MRI scans were performed at Tygerberg Hospital’s CUBIC Unit. These scans were useful in 
excluding other CNS pathologies, as well as being important for other parts of the greater 
HAND research study. Other than for their exclusionary function, they do not form a part of 
this research project. 
 
4.6.1.4.2 Blood investigations 
 
HIV positive participants had blood drawn for tests, including a CD4 count, haemoglobin, 
serum iron, total protein, albumin, vitamin B12 and serum folate, as well as for storage for 
further research investigations such as apolipoprotein E genotyping, and inflammatory and 
neurodegenerative markers.   
 
HIV negative control participants had their HIV status confirmed with ELISA testing. A small 
subgroup (10) had blood taken for storage for future investigations, such as inflammatory and 
degenerative markers.   
 
The blood samples that were not immediately sent to the diagnostic laboratory were spun 
down via centrifuge, to separate the serum, and the serum samples were then archived in a 
freezer in the Groote Schuur Hospital Old Main Building K47, at -80° C. 
 
Unfortunately a serological test for syphilis was not included in the baseline blood 
investigations. As it was felt that this was an important omission,the patients’ clinic records 
and the NHLS database were searched to find results of such tests which were performed by 
chance around the time of the study assessment. Three patients were excluded from further 
analysis within this study due to positive Rapid Plasma Reagin (RPR) results, confirmed with 
fluorescent treponemal antibody-absorption test (FTA-Abs). Of the other 125 who were 
included, a chronologically suitable negative result was able to be found for approximately 
eighty percent. For the rest, no syphilis testing had been performed. All 125 participants were 
included in the results analysis, yet did some further calculations to examine the differences 












4.7 Assessment of raw data 
 
4.7.1 Neuropsychological data: Global Deficit Scores and classification of neuropsychological 
impairment 
 
HIV negative demographically similar control patients (n = 103) underwent testing with a full 
neuropsychological battery, encompassing several different domains of cognitive function. This 
created a set of “normal” raw scores for each test, which allowed computation of the “normal” 
mean and standard deviation for each test, in the specific study population. This was 
important to be able to accurately define impairment in this setting, as there were no 
published normal values for the South African population. From these values, standard scores 
(Z and T scores) (see Figure 4.1) could be calculated for each participant who completed the 
neuropsychological battery. 
 
Z score = raw score of participant – mean score of population 
         standard deviation of population 
 
The T score was calculated from the Z score to avoid the use of negative numbers and 
decimals:   T = 50+10Z (rounded to the nearest whole number). 
 
 
Figure 4.1: The Normal Distribution 
 












Summary scores for each ability domain were calculated by adding the individual Z scores for 
each test covering that domain, and dividing by the number of such tests. The specific scores 
used for each domain were:  non-dominant hand scores for the finger tapping test and 
grooved pegboard test (motor), HVLT recall and BVMT recall scores (learning), MAT and WMS 
III mental control scores (attention), Digit Symbol Coding, TMTA and Colour Trails I (processing 
speed), Colour Trails II, Stroop Colour Word, WCST perseverative errors and RCF copy scores 
(executive function) and animal and fruit/vegetable fluency scores (verbal). This “summary Z 
score” for each domain was then converted to a T score. 
 
T scores were then converted to Deficit Scores, according to the following schema (Heaton et 
al. 1995): 
T scores Deficit Score 





≤ 19 5 
 
The Global Deficit Score was then calculated by adding the deficit scores from each domain, 
and dividing by the total number of added scores. As T scores of 40 or more (which indicate 
performance within normal limits) were assigned a deficit score of 0, whilst T scores in the 
impaired range were assigned progressively higher scores, this method of summarising the 
results from a neuropsychological test battery emphasised poorer performance, which allowed 
for the detection of more subtle impairment that may otherwise be lost in simple mean 
calculations across test results.  
 
A cut point (for determination of global impairment) of ≥0.50 has been shown to have very 
good diagnostic power: sensitivity 0.77, specificity 0.92, positive predictive value 0.88, 
negative predictive value of 0.83 and overall diagnostic accuracy rate (as compared to clinical 
ratings by experienced neuropsychologists) of 0.85. The likelihood ratio of detecting 
neuropsychological impairment is 9.38 (Carey et al. 2004). 
 
In the same study by Carey et al. (2004), it was shown that 93% of the participants who had a 
global deficit score of ≥0.50, also had impairment in at least two ability domains as determined 
by clinical ratings. This is important as the diagnostic criteria for HAND require diagnosis of 











Although the cut point of ≥0.50 has been shown to have the best diagnostic accuracy in terms 
of impairment, different cut points could be used. By definition, a global deficit score of 0 
implies normality, whilst larger numbers imply worse neuropsychological impairment. 
 
For the purpose of this study, the participants were grouped into three categories of 
neuropsychological impairment: normal (GDS <0.25), mild-moderate impairment (0.25 ≤ GDS 
<0.75) and severe impairment (GDS ≥0.75). This approach was devised by Joska et al. (2011c), 
and the three groups were shown to correlate with the HAND diagnoses of normal function, 
ANI/MND (as these essentially have the same degree of neuropsychological impairment, but 
differ on functional status) and HAD. The kappa value for the correlation was 0.491, indicating 
a moderate correlation. 
 
Using this approach instead of the defined HAND categories avoided the need to undertake a 
functional assessment of the participants which has been found to be difficult to do objectively 
(Valcour et al. 2011a). 
 
4.7.2 HAART regimens: CPE ranking 
 
At the time of the follow-up visit, information regarding the participants’ antiretroviral therapy 
was collected. Firstly, whether HAART had been initiated or not. If HAART had been initiated, 
further information was collected, regarding the duration of therapy, as well as the clinical and 
laboratory response to HAART. Details regarding which particular ARV agents had been 
prescribed and taken were also recorded.  
 
This information was then used to classify participants on the basis of their HAART therapy. 
CNS penetration-effectiveness scores were assigned to each antiretroviral agent, according to 


















 Central Nervous System Penetration-Effectiveness Ranking 
Antiretroviral 
Drug Class 




































 Maraviroc  Enfuvirtide 
Integrase strand 
transfer inhibitors 
 Raltegravir   
 
Table 4.2: Revised Central Nervous System Penetration-Effectiveness Ranking 
 
 Letendre S et al. Revised Central Nervous System Penetration-Effectiveness Ranking. 17
th
 Conference on 
Retroviruses and Opportunistic Infections 2010, Abstract 172. 
 
The total regimen score was then calculated by adding the individual scores for each agent in 
the regimen. A total score of seven or less means that the regimen is considered to have poor 
CNS penetration-effectiveness, whilst a total score of more than seven implies good CNS 


















4.8 Laboratory analysis 
 
4.8.1 Preparation of samples 
 
The blood samples that were not immediately sent to the laboratory were prepared for long 
term storage.  The blood collection tubes were centrifuged at 4000rpm for 10minutes, to 
separate the serum, which was then pipetted into suitable cryo-tubes. The serum samples 
were placed in a freezer at -80° C. Some of the samples were stored in the Groote Schuur 
Hospital Old Main Building K47, and some at the Institute of Infectious Diseases and Molecular 
Medicine.  
 
At the time of analysis, the samples were thawed and aliquotted for use in the three different 
tests.  All samples were tested for each analyte in duplicate.  
 
The neopterin and neurofilament heavy chain levels were determined by commercially 
available Enzyme-linked Immunosorbant Assay (ELISA) kits from DRG® and Innovation Beyond 
Limits (IBL) respectively. The assays were performed at Groote Schuur Hospital Old Main 
Building, according to the manufacturers’ instructions. 
 
The osteopontin levels were measured with Luminex technology, at the Centre for Proteomic 
& Genomic Research (CPGR).  
 
4.8.2 Neopterin measurements 
 
The neopterin ELISA kit used was a competitive ELISA from DRG (EIA-1476). As with all ELISAs it 
utilised the ability of antibodies to bind to their corresponding antigens.  
 
In this assay each well of the plate is coated with a polyclonal antibody with a high affinity for 
neopterin. Twenty five microlitres of the standards, controls and samples, which contained the 
unlabelled form of neopterin (the antigen) were added to the wells, together with an enzyme 
conjugate which contained labelled antigen. The labelled and unlabelled antigen then 
competed for the available binding sites on the antibodies present in the well. After a 2 hour 
incubation period, the plate was washed to remove all unbound antigen, before a substrate 
(3,3’,5,5’-Tetramthylbenzidine) was added to allow colour development. After 30 minutes a 











absorbance was read at 450nm using an ELISA plate reader (Organon Teknika Microwell 
System Reader 530).  
 
The absorbance values were inversely proportional to the amount of neopterin in the 
standards and samples, as a higher concentration of unlabelled antigen would mean that less 
labelled antigen would have been able to bind to the antibodies, which would have resulted in 
a weaker colour signal and therefore a lower absorbance reading at the end of the test. 
 
The computer programme, Microsoft Excel, was used to plot the standard curve, by following 
the calculation instructions in the kit manual. Firstly, the average absorbance for each 
standard, control and sample was calculated. Then the percentage of bound antigen was 
calculated.  
 
The net absorbance was determined by subtracting the n n-specific binding (blank) 
absorbance from the sample absorbance value. This net absorbance is then divided by the net 
zero standard absorbance (the absorbance in these wells should be 100%) to obtain the 
percentage bound. 
 
%B/Bo = Abs (sample) – Abs (NSB) x  100 
 Abs (zero std) – Abs (NSB)  
 
A graph was then created for the standard values, with the percentage bound on the Y axis 
and the concentration of neopterin on the X axis. This standard curve was then used to 
determine the neopterin concentration for each sample, using the calculated percent bound.  
 
4.8.3 Neurofilament heavy chain measurements 
 
The Human Phosphorylated Neurofilament H ELISA kit was obtained from Biovendor: Research 
and Diagnostic Products (RD191138300R). It was a sandwich ELISA, used to detect sample 
antigen. The plate wells were pre-coated with chicken polyclonal anti-pNF-H antibody. One 
hundred microlitres each of sample (diluted three fold as required in the instruction manual), 
standards and quality controls (containing the antigen) were then added and incubated for an 
hour. After washing, a detection antibody (rabbit polyclonal anti-pNF-H) was added and the 
plate incubated again for one hour.  After washing, HRP conjugated antibody against the rabbit 











Chicken polyclonal anti-pNF-H antibody
Rabbit polyclonal anti-pNF-H antibody
HRP conjugated antibody (with enzyme)
Antigen (pNF-H)
Substrate solution (converted to detectable form by enzyme on HRP conjugated antibody)
(one hour), and a final wash, the substrate solution (3,3’,5,5’-Tetramthylbenzidine) was added 
to bind to the conjugated antibody. After 15 minutes, a stop solution was added, and the 
absorbance was then read with a microplate reader (Organon Teknika Microwell System 
Reader 530) set at 450nm, with the reference wavelength set to 620nm. The absorbance was 



















Figure 4.2: Sandwich ELISA principle 
 
Modified from: Vinocur JM. ELISA.Wikipedia.org. 2006   
[http://en.wikipedia.org/wiki/ELISA – accessed 18/11/2011] 
 
The computer programme Microsoft Excel was then used to generate the standard curve, by 
plotting the absorbance values of the standards, against their known concentrations. The 
equation defining this standard curve was then calculated, and used to determine the 
concentration of pNF-H in each sample by using the absorbance values. 
 
4.8.4 Osteopontin measurements 
 
Osteopontin was measured in the samples using Luminex® xMAP® technology, and a Milliplex® 
MAP kit (cat. # HBN1A-51K). The procedures were performed at the Centre for Proteomic and 
Genomic Research, by the laboratory technicians, according to the manufacturers’ instructions 
included in the kit.  
 
Luminex® xMAP® technology utilises fluorescent-coded beads (minute polystyrene 











cytometry principles to enable detection of multiple analytes on a single sample volume 
(Luminex Corporation; Milliplex MAP HBN1A-51K kit book). 
 
Each microsphere set was colour-coded with a specific concentration of the two dyes to allow 
a unique signal. Each bead was then coated with a specific capture antibody to bind its 
designated analyte once the sample (12.5uL) was added to the microplate wells. Thereafter a 
biotinylated detection antibody was introduced, and then incubated with Streptavidin-
Phycoerythrin conjugate, which was the reporter molecule (Luminex Corporation; Milliplex 
MAP HBN1A-51K kit book) (See Figure 4.3). 
 
 
    
Figure 4.3: xMAP® technology bead 
 
From: http://www.biotekinstruments.ru/ru/resources/articles/wash-luminex-xmap-assays.html  
[Accessed 04/01/2012] 
 
The microspheres were then passed through the Luminex analyser, in a similar way to that 
used with flow cytometry. A red laser excited the dyes within the microspheres which allowed 
for classification of the type of microsphere (that is, what the bead had been labelled to 
measure). A second laser then excited the phycoerythrin fluorescent label, which, as the 
reporter molecule, showed binding of the analyte (See Figure 4.4). Multiple readings were 
performed for each bead set to validate the result. Digital signal processers within the Luminex 
analyser then quantified the results of the bioassay according to the fluorescent signals read, 
and sent the results (including the standard curve) directly to the attached computer system 

















The kit used in this project was a Human Bone Panel Kit (1A), which allowed for the 
measurement of seven different analytes for each sample. However, as only osteopon
of interest in this project, the other beads were not utilised.      
 
4.9 Collation of data
 
All data from the larger studies were compiled onto a Microsoft Excel spreadsheet, by the data 
capturers. The data collected
from the second cohort of HIV positive participants, the HAART data with revised CPE scores, 
the RPR data and all the biomarker data
 
The data were then prepared for analysis. Missing data were followed up 
and added where possible.
 
4.10 Analysis of data
 
The data were then transferred into the Statistics/Data Analysis (STATA®) Software 
programme (version 11) for statistical analysis. The level of statistical significance was set at 
= 0.05. Distributions of the variables were determined using the Shapiro
parametric or nonparametric methods used as appropriate. Further details on specific analyses 
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4.11 Summary of methods: flow diagram of the study process 
 
 
Figure 4.5: Flow diagram of study process 
*The available neopterin kits only allowed for the measurement of 101 samples. NFH and OPN kits allowed for the 
measurement of 104 samples. 3 participants had to be excluded once found to be RPR positive. CPGR samples had 
already gone for processing once this was discovered, therefore only 101 useable sample results were yielded for 
OPN. For neopterin and NFH, 1 of the RPR positive participants’ blood had already been analysed, however, in order 
not to waste the kits, I randomly selected 2 further participants from cohort 1 with baseline scores only and blood 
samples available (the rest of the data from these 2 participants were also included in the study). Therefore 100 
neopterin, and 103 NFH measurements were yielded.  
** The 115 included from cohort 1 is made up of the 105 who satisfactorily completed follow-up, as well as the 10 















Neopterin n = 100
Osteopontin n =  101
NFH n = 103
111 total with HAART 
data:
89 on HAART (69 pure 
regimens, ≥ 10 months)
22 not on HAART (20 





283 screened Still ongoing
166 completed baseline assessments
(24 excluded: baseline data only, no 
blood samples) [142]
± 150 completed baseline 
assessments to-date
Subgroup within correct time period 
for this study: 26 [26]
108 completed follow-up
(then 3 excluded: 1x RPR pos; 2x 
virological failure on HAART at 
follow-up)
(34 lost to follow-up)                   [105]
13 completed reassessments 
(3 excluded: 1 follow-up participant 
excluded – no blood, unsatisfactory 
response to HAART, 2 excluded once 
discovered RPR pos)
(13 lost to follow-up) [10]
85: follow-up data and 
bloods
(20 excluded – f/up data 
but no blood samples)
54: baseline data only and 
bloods – 10 randomly 
selected [95]
10 samples traced
(2 of these later discovered to be 
RPR pos and excluded) therefore, 8 
with follow-up data and blood [8]
101 with follow-up and HAART data
(4 – excluded because no HAART data) 
[101]













Chapter 5 – Results of the study 
 
5.1 Subject characteristics 
 





           with follow-up data  [115] 
           with HAART data  [111] 
           With blood samples for biomarker analysis [103] 
           With follow-up data and blood samples [93] 
 
HIV negative controls 
Total 123 
          Young, demographically similar to HIV+ for NP testing (and blood samples) 
          (cognitively normal) 
[103 (10)] 
          Old, probable Alzheimer’s disease patients (cognitively impaired) [10] 




 Table 5.1: Breakdown of study participant numbers 
*125 is the total of the 115 participants who completed follow-up together with the 10 participants 
whose baseline data and blood samples were utilised for the biomarker analysis. 
 
Demographic characteristics, including sex, age, years of education and home language were 
collected where possible for all participants. CD4 count data were collected for the HIV 
positive participants. A Shapiro-Wilk Test was performed for the continuous variables. Years of 
education was found to have a normal distribution (SW, p = 0.070), as were the baseline CD4 
counts (SW, p-value 0.400) and follow-up CD4 counts (SW, p = 0.190). Age was analysed 
separately for the two distinct age ranges in the study, the younger groups (SW, p = 0.090) and 
the older groups (SW, p = 0.250). Categorical data were analysed with percentage distributions 













 Mean  age  
± SD 
(in years) 
Sex Mean level of 
education  ±  SD    
(in years) 
Home language Mean baseline CD4 count ± SD  
(in cells/ul)* 
Mean follow-up CD4 




n = 125 
29.7  
± 3.43 
77%  Female 







(Test Language: 64% Xhosa; 35% 






n = 69* 
29.4  
± 3.2 
75%  Female 











n = 20* 
30.2 
± 3.6 
70%  Female 












similar to HIV + 
n = 103** 
25.3 
± 5.0 
63%  Female 






(Test Language: 84% Xhosa, 13% 
English; 3% Afrikaans) 
N/A N/A  
 
Probable AD 
n = 10 
74.2 
± 7.7 
50%  Female 





(Test Language: 100% English) 
N/A  N/A  
Demographically 
similar to AD 
n = 10 
75.1 
± 4.6 
80%  Female 





(Test Language: 100% English) 
N/A  N/A  
Table 5.2: Demographic characteristics of study participants  
(SD = standard deviation; n = count; N/A = not applicable) 
*Only those with baseline CD4 count <350 cells/ul were included in these calculations, as this was the group used for all further calculations where CD4 count was important. (n = 120 for total HIV+ with CD4 count <350 
cells/ul).  **The HIV negative demographically similar control group comprised 103 participants, who underwent neuropsychological testing to determine the specific population norms. Additionally, 10 of these 
participants had blood drawn for investigations. The demographic details of this subgroup of 10 participants were also characterised. All of the comparisons detailed in the text and tables over the next few pages 
(between this control group (103) and the other study groups) were also conducted for the subgroup of 10. The findings that were significant in the comparisons with the larger group (103), remained significant when the 












Comparisons of the demographic characteristics were done across the groups using one-way 
analysis of variance (ANOVA) tests. The groups were found to be comparable in terms of 
gender [F (3, 239)* = 2.46, p = 0.063] but significantly different in terms of age [F (3, 238) = 
670.40, p = <0.001] and level of education [F (3, 238) = 17.82, p = <0.001]. (*= degrees of 
freedom between groups, within groups).  
 
The age difference was to be expected given the obviously different age ranges for the HIV and 
AD studies respectively. In order to take the above differences into account, a comparison was 
done between the demographically similar groups. The HIV positive group was compared to its 
demographically similar group (see Table 5.3), and the Alzheimer’s disease group was 
compared to its demographically similar group (see Table 5.5), using Student’s t-tests for age 
and education, and a Chi-squared test for sex. 
 
 HIV+ Young Controls df t p 
Age in years 29.7 (3.4) 25.3 (5.1) 221 7.76 < 0.001 
Education in years 10.1 (1.8) 10.8 (1.4) 221 -3.08 0.002 
Sex 77%  Female 
23%  Male 
63%  Female 
37%  Male 
χ
2 
 =  4.87 
df = 1 
p = 0.027 
 
Table 5.3: Demographic comparison of HIV positive participants and cognitively healthy young 
controls 
Means are presented with standard deviations in parentheses. 
df = degrees of freedom; t = statistic t; p = p value 
 
The young control group was recruited from the same areas, with the same criteria (except for 
HIV status) as the HIV positive group (see Table 5.4). When subjected to statistical testing 
however, these two groups are in fact not significantly demographically similar (see Table 5.3).  
The HIV positive group was slightly older, with a lower level of education. There were also 
proportionally fewer males in the HIV positive group. Although statistically significantly 

















Recruitment clinic % of HIV positive group 
recruited from each clinic 
% of HIV negative control group 
recruited from each clinic 
Nolungile Clinic, Khayelitsha 79% 81% 
Woodstock Clinic 17% 19% 
Mitchells Plain CHC 4% 0% 
 
Table 5.4: Percentage distribution from recruitment clinics 
 
As detailed in Table 5.5, the Alzheimer’s disease group was a similar age to its control group, 
however had, on average, fewer years of education. The sex distribution was equal in the AD 
group, but there were more females than males in the control group. 
 
 AD Old Controls df t P 
Age 74.2 (7.7) 75.1 (4.6) 17 -0.03 0.761 
Education 10.1 (4.4) 14.6 (3.9) 17 -2.36 0.031 
Sex 50%  Female 
50%  Male 
80%  Female 
20%  Male 
χ
2
 = 42.65 
df = 1 
p = < 0.001 
 
Table 5.5: Demographic comparison of Alzheimer’s disease participants and cognitively healthy 
older controls 
Means are presented with standard deviations in parentheses.  
df = degrees of freedom; t = statistic t; p = p value 
 
The HIV positive group was the main focus of this study and therefore further baseline analysis 
was done for this group. Two areas needed to be explored further to allow for the later 
analyses to test the stated hypotheses. 
 
Firstly, the group needed to be analysed and compared in terms of cognitive functional ability. 
Three groups were created according to baseline global deficit score, as described in the 
methods section (see 4.7.1, p49). A comparison of baseline characteristics was done using one-
way ANOVA tests. The breakdown of numbers and the results of the ANOVAs are shown in 
Table 5.6. The only significant difference between the groups was found in terms of the level 















Baseline cognitive function groups (HIV+ group) 
 Normal 








One-way ANOVA results 
 n = 52 
(median GDS = 
0) 
n = 37 
(median GDS = 
0.53) 
n = 36 
(median GDS = 
1.14)  
F (df) P 
Mean 
baseline 
CD4 ± SD 
















16.53 (2, 122) <0.001 
Sex 83%  Female 
17%  Male 
70%  Female 
30%  Male 
75%  Female 
25%  Male 
0.97 (2, 122) 0.381 








1.01 (14, 110) 0.450 
 
Table 5.6: Comparison of HIV positive baseline cognitive function groups (all HIV positive 
participants) 
n = count; SD = standard deviation; F = statistic F; (df) = degrees of freedom between groups and within 
groups); p = p value 
 
Table 5.7 below shows the numbers once the groups have been adjusted to include only those 
with CD4 count <350 cells/ul and HAART data (either no HAART or one HAART regimen for at 
least 10 months). These smaller groups were required to meet the conditions stated in some 
of the hypotheses. Once again, the only significant difference between the three groups was in 
terms of the level of education. The most severely impaired group had the lowest level of 
education, the mild to moderately impaired group the second lowest, and the normal group, 
































One-way ANOVA results 
 n = 41 n = 30 n = 18 F (df) P 
Mean 
baseline CD4 
count (in cells 







0.86 (70, 17) 0.683 
Mean level of 
education (in 







5.96 (8, 80) <0.001 
Sex 83%  Female 
17%  Male 
63%  Female 
37%  Male 
72%  Female 
28%  Male 
1.52 (1, 87) 0.221 
Mean age (in 







0.73 (12, 76) 0.719 
 
Table 5.7: Comparison of HIV positive baseline cognitive function groups (participants with CD4 
count less than 350 cells/ul and HAART information)  
n = count; SD = standard deviation; F = statistic F; (df) = degrees of freedom between groups and within 
groups); p = p value 
 
In order to analyse the effect of HAART on cognitive function, baseline analysis was conducted 
to determine the characteristics of the different groups. HAART information was only 
obtainable from those participants who returned for follow-up assessment. The median 
follow-up period was 12 months, interquartile range was 3 months. HAART data were obtained 
for 111 of the 115 participants who completed follow-up. (Reasons for not having HAART data 
were patient uncertainty on details and unclear recording of details on data capture forms.) 
 
Of these 111 participants, 89 had been initiated on HAART since the baseline assessment, 
whilst 22 had not. Once those whose CD4 counts were greater than 350 cells/ul, and those 
who had not been on only one HAART regimen for at least 10 months, were excluded, the 
numbers for the HAART analysis became 69 on HAART and 20 not on HAART. 
 
 HAART 
n = 69 
No HAART 
n = 20 
Statistical comparisons 
Mean baseline CD4 





t-test:  df 86, t = -1.10, p = 0.275  






Wilcoxon rank-sum test: 
 z = -0.154 , p = 0.878 
 
Table 5.8: Comparison of the groups who did and did not receive HAART 
n = count; SD = standard deviation; IQR = interquartile range; df = degrees of freedom; t = statistic t; p= 











The HAART and no HAART groups were not significantly different in terms of baseline CD4 
count or baseline GDS. 
 
For the CPE analysis, the group of participants on one consistent regimen of HAART for more 
than 10 months were examined (n = 69). Table 5.9 shows the distribution of participants 
across the CPE categories. As the numbers in each smaller group were so small, no further 
demographic comparisons were done. 
 
CPE of HAART Regimen n = CPE category Total n for category 
6 10 Low 
 
31 
 7 21 







Table 5.9: Breakdown of CNS penetration-effectiveness (CPE) categories 
n = count 
 
A final baseline characteristic that was examined was the effect of knowing the RPR status of 
the participants. As stated in the methods section, syphilis testing was not part of the larger 
study protocol and was therefore not performed at the baseline assessment. It was felt that 
this information was important given the high prevalence of sexually transmitted infections in 
the South African population and the potential neurological effects of syphilis infection. 
Results of syphilis testing done for the participants at local clinics, at approximately the time of 
the baseline assessment, were therefore traced. Participants discovered to be RPR positive 
were immediately excluded from the study (n = 3). For the other 125 participants, it was 
possible to trace negative results for 99. The other 26 participants appeared not to have been 
tested.  It was therefore decided to examine the other baseline characteristics with respect to 


















 RPR negative RPR unknown Statistical comparisons 
Mean age (in 




± 3.04  
t-test: 123 df, t = -0.80 , p = 0.425   
Mean level  of 
education (in 
years) ± SD 
10.22 
± 1.74  
9.58  
± 1.98  
t-test: 123 df, t = 1.64 , p = 0.104  
Sex 75%  Female 
25%  Male 
81%  Female 
19%  Male 
t-test:  123 df, t = 0.54 , p = 0.594  
Mean baseline 
CD4 count (in 
cells/ul) ± SD 
181.13  
± 99.52  
181.42 
± 120.01 
t-test:  122 df, t = 0.01 , p = 0.992  
Median baseline 
GDS (IQR) 
0.33 (0.73)  0.73 (1.0)  Wilcoxon rank-sum test:  
z = -2.41, p = 0.016 
GDS change 
(IQR) 
0 (0.27) -0.2 (0.47)  Wilcoxon rank-sum test:  
z =  1.99, p = 0.046 
 
Table 5.10: Comparison of the groups in which RPR was negative and unknown 
SD = standard deviation; IQR = interquartile range; df = degrees of freedom; t = statistic t; p= p value; z = 
statistic z 
 
Table 5.10 shows the two groups to be equal in terms of age, level of education, sex 
distribution and baseline CD4 count. The groups were however different in terms of baseline 
GDS: the RPR unknown group had a higher median score, indicating poorer cognitive function. 
The GDS change was also greater for the RPR unknown group, which means they had greater 
improvement in cognitive function at follow-up. 
 
A Kruskal-Wallis test was used to examine possible differences in the baseline cognitive 
function groups, according to the distribution of RPR negative to RPR unknown. A significant 
difference was detected. χ2 = 4.14, 1 df, p = 0.042. Table 5.11 shows that there were 
proportionately more RPR unknowns in the severely impaired group than in the other two 
baseline cognitive function groups.   
 
 RPR negative RPR unknown 
Normal 
GDS < 0.25 
n = 45 n = 7 
Mild-Moderate Impairment 
0.25 ≤ GDS <0.75 
n = 30 
 
n = 7 
Severe Impairment 
GDS  ≥0.75 
n = 24 n = 12 
 
Table 5.11: Breakdown of numbers in the baseline cognitive function groups according to RPR 











5.2 Results by Hypothesis 
 
5.2.1 Hypothesis one and two 
 
Hypothesis one stated that HAART of at least ten months would improve cognitive function in 
HIV positive ARV-naïve patients with a CD4 count of less than 350 cells/ul and cognitive 
dysfunction at baseline; that is, participants with impaired cognitive function at baseline, 
would show improvement one year later, after at least ten months of HAART therapy, while 
participants with impaired cognitive function at baseline, and a CD4 count less than 350 
cells/ul, who had not been on HAART therapy, would not show improvement one year later. 
 
Hypothesis two stated that HAART would be protective of cognitive function; that is, HIV 
positive patients with normal cognitive function at baseline who then used HAART for at least 
ten months, would still have normal cognitive function at the one year follow-up visit, as 
opposed to HIV positive patients with normal cognitive function at baseline who did not have 
exposure to HAART. 
 
The entire group of HIV positive participants with follow-up data (n = 115) was analysed. How 
many of these participants maintained or improved their cognitive function, and how many 
worsened in terms of cognitive function was assessed. This was done by looking at the follow-
up GDS with respect to the baseline GDS. As less than 0.25 is considered normal, and 
progressively higher numb rs indicate worsening cognitive function, a positive change in GDS 
score indicates worsening, whilst a negative change indicates improvement. No change in GDS 
implies maintenance of cognitive function at the baseline level. Table 5.12 shows that the 
majority of the HIV positive study participants maintained or improved their cognitive function 
after one year. 
 
All HIV+ with follow-up data    (n = 115) 







 Table 5.12: Distribution of cognitive responses at follow-up 











The change in cognitive function with respect to HAART status was then analysed. Only those 
with CD4 count less than 350 cells/ul, and those either not  on HAART, or on HAART for at least 
ten months were included, as stipulated in the hypotheses (n = 89) (See Table 5.13). 
 
 GDS change 
category 
breakdown 









n = 69 
Maintained or 
improved cognitive 




df = 1 
p = 0.017 
-0.07 (0.27) z = -2.09 
p = 0.036 
Worsened cognitive 
function = 13 (19%) 
No HAART 
n = 20 
Maintained or 
improved cognitive 
function = 11 (55%) 
0 (0.36) 
Worsened cognitive 
function = 9 (45%) 
 
Table 5.13: Comparison of cognitive responses at follow-up between the HAART and no HAART 
groups 
n = count; χ
2 
= chi-squared; df = degrees of freedom; p = p value; t = statistic t; z = statistic z 
 
A Pearson’s Chi-squared test was performed to compare the change in cognitive function 
categories, and this indicated a significant difference in cognitive response between the two 
groups (HAART and no HAART). χ
2
 (1, n = 89) = 5.70, p = 0.017. More of those who received 
HAART maintained or improved cognitive function than those who had not received HAART. A 
Wilcoxon rank-sum test was also performed to compare the actual GDS change as a 
continuous variable between the two groups. Again, a significant difference was detected, with 
the HAART group having a greater GDS improvement. z = -2.09, p = 0.036.  This indicates that 
HAART is beneficial for cognitive function in those with CD4 count less than 350 cells/ul. This is 
in keeping with hypothesis one. 
 
A Kruskal-Wallis test was done to compare GDS change across the baseline cognitive function 
groups. (This test was chosen due to the non-parametric distribution of the GDS change 
variable. SW, p = < 0.001. Of note, baseline GDS was also found to have a non-parametric 












There were significant differences in GDS change between the three baseline cognitive 
function groups, for the HIV positive group with follow-up data as a whole (Table 5.14), as well 
as those who had received HAART for at least ten months (Table 5.15). In both instances, the 
most severely impaired group had the greatest improvement in GDS at one year.  This 
indicated that GDS change was also associated with the baseline level of cognitive function; 
that is, those that were more cognitively impaired to begin with, had a greater improvement in 
GDS change after one year. Figure 5.1 and 5.2 reflect this graphically. 
 








GDS < 0.25 
n = 51 
0 (0.13) 0 (0.13) χ
2
= 33.26 
df = 2 
p = < 0.001 
 
Mild-Moderate Impairment 
0.25 ≤ GDS <0.75 
n = 37 
0.53 (0.34) -0.13 (0.33) 
Severe Impairment 
GDS ≥0.75 
n = 27 
1.07 (0.60) -0.67 (0.6) 
 
Table 5.14: Comparison of median GDS change across the baseline cognitive function groups 
n = count; χ
2 




















Figure 5.1: Comparison of median GDS change across the baseline cognitive function groups 
(NB: GDS change of “0” implies maintenance of cognitive function; negative GDS change implies improvement; 



































For HIV+ participants with follow up data, and on HAART ≥ 10 months (n = 69) 
 Median baseline 
GDS (IQR) 




GDS < 0.25 
n = 33 
0 (0.13) 0 (0) χ
2 
= 19.74 
df = 2 




0.25 ≤ GDS <0.75 
n = 21 
0.60 (0.27) -0.2 (0.46) 
Severe Impairment 
GDS ≥0.75 
n = 15 
1.20 (0.66) -0.47 (0.67) 
 
Table 5.15: Comparison of median GDS change across the baseline cognitive function groups 
(in the subgroup who received HAART) 
n = count; χ
2 






















Figure 5.2: Comparison of median GDS change across the baseline cognitive function groups (in 
the subgroup who received HAART) (NB: GDS change of ”0” implies maintenance of cognitive function; 
negative GDS change implies improvement; positive GDS change implies worsening.) 
 
Further analysis was done to examine the effect of HAART on cognitive change at one year, 
within the baseline cognitive function groups (see Table 5.16). A significant difference in GDS 
change attributable to HAART, was found only for those with normal cognitive function: those 
who received HAART maintained their GDS at one year, whilst those without HAART 





































supports hypothesis two. The result for those with mild-moderate impairment bordered on 
significance, with those receiving HAART having a much greater improvement in GDS than 























GDS < 0.25 
HAART 
(n = 33) 
Maintained or 
improved cognitive 
function = 26 (79%) 
p = 0.034 0 (0) z = -2.33 
p = 0 .020   
Worsened cognitive 
function = 7 (21%) 
No HAART 
(n = 8) 
Maintained or 
improved cognitive 
function = 3 (38%) 
0.1 (0.27) 
Worsened cognitive 






(n = 21) 
Maintained or 
improved cognitive 
function = 18 (85%) 
p = 0.237 -0.24 (0.46) z = -1.95 
p =  0.051 
Worsened cognitive 




(n = 9) 
Maintained or 
improved cognitive 
function = 6 (67%) 
-0.07 (0.2) 
Worsened cognitive 






(n = 15) 
Maintained or 
improved cognitive 
function = 12 (80%) 
p = 0.554 -0.47 (0.67) z  = -0.594 
p =  0.553 
Worsened cognitive 
function = 3 (20%) 
No HAART 
(n = 3) 
Maintained or 
improved cognitive 
function = 2 (67%) 
-0.27 (1.27) 
Worsened cognitive 
function = 1 (33%) 
 
Table 5.16: Comparison of cognitive responses at follow-up between the HAART and no HAART 
groups, across the baseline cognitive function groups           











5.2.2 Hypothesis three 
 
Hypothesis three stated that HAART regimens with greater CNS penetration-effectiveness 
(regimen CPE more than seven) would be more effective in improving cognitive outcomes in 
HIV positive patients, compared with HAART regimens with a lower CNS penetration-
effectiveness (regimen CPE less than or equal to seven); such that patients on HAART regimens 
with a CPE of more than seven would have a greater improvement in cognitive function at the 
one year follow-up visit, than those on regimens with a CPE of less than or equal to seven. 
 
Table 5.17 reiterates the breakdown of participants according to the CPE categories.  A total of 
69 participants were included in this analysis. 
 
Breakdown of CPE categories (pure HAART regimens, ≥10 months, only.  Total n = 69) 
CPE of HAART Regimen n = CPE category Total n for category 
6 10 low 
 
31 
 7 21 






Table 5.17: Breakdown of CNS penetration-effectiveness (CPE) categories 
n = count 
 
A two-by-two table (Table 5.18) was constructed and a Pearson’s Chi-squared test performed 
to examine the effect of CPE category on cognitive response at the one year follow-up visit.  
No significant difference in cognitive response between the two groups (high and low CPE) was 
found. χ
2 
(1, n = 69) = 0.51, p = 0.473.  
 




32 (84%) 24 (77%) 58 
Worsened cognitive 
function 
6 (16%) 7 (23%) 13 
Total 38 31  
 













A comparison of median GDS change between the two groups (low CPE and high CPE) was also 
done, using a Wilcoxon rank-sum test (see Table 5.19). No significant difference was found. 
 
 Median GDS change (IQR) Wilcoxon rank-sum test to 
compare GDS change  
Low CPE 0 (0.2) z = 0.99 
p = 0.320 High CPE -0.13 (0.4) 
 
Table 5.19: Comparison of median GDS change at follow-up between the high and low CPE 
groups 
IQR = interquartile range; z = statistic z, p = p value  
 
Table 5.20 shows the effect of CPE category on cognitive response at one year (within the 
baseline cognitive function groups), using a categorical variable (cognitive response category) 
as well as a continuous variable (median GDS change). Fisher’s Exact tests were done for the 
categorical variable and Wilcoxon rank-sum tests for the continuous variable. No significant 

















































GDS < 0.25 
Low CPE 
(n = 15) 
Maintained or 
improved cognitive 
function = 13 
(87%) 
p = 0.283 0  
(0) 
z = -0.54 
p = 0.587 
Worsened 
cognitive function 
= 2 (13%) 
High CPE 
(n = 18 ) 
Maintained or 
improved cognitive 






= 5 (28%) 
Mild-Moderate 
Impairment 




(n = 10 ) 
Maintained or 
improved cognitive 
function = 7 (70%) 
p = 0.090 -0.2 
(0.67) 
z = 0.53 
p = 0.596 
Worsened 
cognitive function 
= 3 (30%) 
High CPE 
(n  = 11) 
Maintained or 
improved cognitive 









GDS ≥ 0.75 
 
Low CPE 
(n = 6) 
Maintained or 
improved cognitive 
function = 4 (67%) 
p = 0.341 -0.34 
(1.80) 
z  = 1.18 
p = 0.237 
Worsened 
cognitive function 
= 2 (33%) 
High CPE 
(n = 9) 
Maintained or 
improved cognitive 





= 1 (11%) 
 
Table 5.20: Comparison of cognitive responses at follow-up between the high and low CPE 
groups across the baseline cognitive function categories.  











The CPE groups were then examined directly; that is, without categorisation into high and low. 
Below is a breakdown of the numbers found in each baseline cognitive function group (Table 
5.21). 
 
 Revised CPE  
Baseline cognitive 
function group 















































Totals  10 21 13 5 20 69 
 
Table 5.21: Breakdown of number of participants according to regimen CPE score and baseline 
cognitive function group  
 
A Kruskal-Wallis test was done to compare the median GDS change across the CPE divisions. 
No statistically significant difference was found (see Table 5.22). 
 








df = 4 









Table 5.22: Comparison of median GDS change across the regimen CPE groups 
CPE = CNS penetration-effectiveness score; IQR = interquartile range; χ
2
= Chi-squared; df = 












Finally just the lowest CPE regimen was compared with the highest, namely CPE = 6 and CPE = 
10, to look for differences in terms of effect on cognitive function. No significant result was 
found (Table 5.23). 
 







test to compare GDS 
change 
CPE =  6 
(n = 10) 
Maintained or improved 
cognitive function = 6 
(60%) 
p = 0.143 0 
(0.33) 
z = 1.67 
p = 0.095 
Worsened cognitive 
function = 4 (40%) 
CPE = 10 
(n = 20) 
Maintained or improved 





function = 3 (15%) 
 
 
Table 5.23: Comparison of highest and lowest regimen CPE according to cognitive response at 
follow-up 
CPE = CNS penetration-effectiveness score; n = count; IQR = interquartile range; p = p value; z =statistic z  
 
Overall, no difference was found in terms of cognitive outcomes at one year, in participants 












5.2.3 Hypothesis four 
 
Hypothesis four stated that serum levels of the inflammatory markers neopterin, osteopontin 
and the neurodegenerative marker neurofilament heavy chain would be significantly different 




The distribution of the neopterin values for the samples was found to be not normal when a 
Shapiro-Wilk test was applied (SW, p = < 0.001). Non-parametric analysis methods were thus 
used. 
 
The median neopterin levels in each group were compared using a Kruskal-Wallis test, and a 
significant difference was detected (see Table 5.24): the HIV positive group had much higher 
median neopterin levels than any of the HIV negative groups. Figure 5.3 shows this graphically. 
 




(n = 100) 
4.00 (3.73)  
χ
2 
 = 38.65 
df = 3 
p = < 0.001 
HIV- , young, demographically 
similar to HIV+  
(n = 10) 
1.81 (0.34) 
HIV- , probable AD  
(n = 10) 
1.98 (0.93) 
HIV- , old, demographically 
similar to AD  
(n = 10) 
2.22 (1.47) 
 
Table 5.24: Comparison of median serum neopterin levels across the study participant groups  
n = count; IQR = interquartile range; + = positive; - = negative; χ
2
= Chi-squared; df = degrees of freedom; 













Figure 5.3: Comparison of serum neopterin levels across the study participant groups 
  
The median neopterin levels in the control groups only, were then compared using Kruskal-
Wallis tests. No significant difference was found (Table 5.25).  
 
 Kruskal-Wallis Test 




 = 0.11 
df = 2 
p = 0.946 
AD versus old controls χ
2 
 = 0.02 
df = 1 
p = 0.880 





df = 1 
p = 0.940 
 
Table 5.25: Comparisons of median serum neopterin levels across the control groups 
χ
2
= Chi-squared; df = degrees of freedom; p = p value 
 
The HIV positive, cognitively normal participants were then compared to the young, 
demographically similar HIV negative participants, in terms of median neopterin level, by using 








































 Median neopterin 






n = 37 
3.86 (2.80) z = 3.87 




n = 10 
1.81 (0.34) 
 
Table 5.26: Comparison of median neopterin levels between cognitively normal 
demographically similar participants, differing only in terms of HIV status. 
n = count; IQR = interquartile range; z = statistic z; p = p value  
 
The HIV positive, cognitively impaired participants were then compared to the probable AD 
participants, in terms of median neopterin level, by using a Wilcoxon rank-sum test. A 
significant difference was found: z = 3.738, p = < 0.001 (See Table 5.27). 
 
 Median neopterin 






n = 63 
4.28 (3.82) z = 3.74 
p = < 0.001 
HIV negative, 
probable AD controls 
n = 10 
1.98 (0.93) 
 
Table 5.27: Comparison of median neopterin levels between cognitively impaired HIV positive 
participants and cognitively impaired HIV negative participants (AD). 
n = count; IQR = interquartile range; z = statistic z; p = p value 
 
Finally, the HIV positive, cognitively impaired participants together with the AD participants, 
were compared (as one group) to the cognitively normal controls (as one group) in terms of 
median neopterin level, by using a Wilcoxon rank-sum test. A significant difference was found. 
















 Median neopterin 





n = 73 
3.63 (4.00) z = 4.46 
p = < 0.001 
All cognitively normal 
participants 
n = 20 
1.82 (1.06) 
 
Table 5.28: Comparison of median neopterin levels between cognitively impaired and 
cognitively normal participants, regardless of HIV status 
n = count; IQR = interquartile range; z = statistic z; p = p value 
 
These results, taken in conjunction with the above results, support hypothesis four, in terms of 
neopterin. That is, that neopterin levels in the HIV positive group were significantly different to 














The distribution of the osteopontin values for the samples was found to be not normal when a 
Shapiro-Wilk test was applied (SW, p = < 0.001). Non-parametric analysis methods were thus 
used. 
 
The median osteopontin levels in each group were compared. No significant difference was 
detected (see Table 5.29). Figure 5.4 shows this graphically.  
 








df = 3 
p = 0.370 HIV-, young, demographically 
similar to HIV+ 
(n = 10) 
509.05 (293.3) 
HIV-, probable AD 
(n = 10) 
266.15 (422.0) 
HIV-, old, demographically 
similar to AD 
(n = 10) 
456.4 (254.2) 
 
Table 5.29: Comparison of median serum osteopontin levels across the study participant 
groups  
n = count; IQR = interquartile range; + = positive; - = negative; χ
2
= Chi-squared; df = degrees of freedom; 















Figure 5.4: Comparison of serum osteopontin levels across the study participant groups 
 
The median osteopontin levels in the control groups only were then compared using Kruskal-
Wallis tests. No significant difference was found (Table 5.30).  
 
 Kruskal-Wallis Test 





df = 2 
p = 0.233 
AD versus old controls χ
2 
= 0.69 
df = 1 
p = 0.406 





df = 1 
p = 0.545 
 
Table 5.30: Comparisons of median serum osteopontin levels across the control groups 
χ
2
= Chi-squared; df = degrees of freedom; p = p value 
 
The HIV positive, cognitively normal participants were then compared to the young, 
demographically similar HIV negative participants, in terms of median osteopontin level, by 













































 Median osteopontin 






n = 37 
232 (526.8) z = -1.61 




n = 10 
509.05 (293.3) 
 
Table 5.31: Comparison of median osteopontin levels between cognitively normal 
demographically similar participants, differing only in terms of HIV status. 
n = count; IQR = interquartile range; z = statistic z; p = p value  
 
The HIV positive, cognitively impaired participants were then compared to the probable AD 
participants, in terms of median osteopontin level, by using a Wilcoxon rank-sum test. No 
significant difference was found. z = 0.142, p = 0.887 (Table 5.32). 
 
 Median osteopontin 






n = 64 
291.15 (615) z = 0.142 
p = 0.887 
HIV negative, 
probable AD controls 
n = 10 
266.15 (422) 
 
Table 5.32: Comparison of median serum osteopontin levels between cognitively impaired HIV 
positive participants and cognitively impaired HIV negative participants (AD). 
n = count; IQR = interquartile range; z = statistic z; p = p value 
 
Finally, the HIV positive, cognitively impaired participants together with the AD participants, 
were compared (as one group) to the cognitively normal controls (as one group) in terms of 
median osteopontin level, by using a Wilcoxon rank-sum test. No significant difference was 















 Median neopterin 





n = 74 
291.15 (569.7) z = -1.45 
p = 0.147 
All cognitively normal 
participants 
n = 20 
456.9 (256) 
 
Table 5.33: Comparison of median osteopontin levels between cognitively impaired and 
cognitively normal participants, regardless of HIV status 
n = count; IQR = interquartile range; z = statistic z; p = p value 
 
As no significant results were found in the osteopontin analysis, hypothesis four has not been 
proven for osteopontin. 
 
Neurofilament H protein 
 
Unfortunately the neurofilament heavy chain assays only yielded results for 2 of the samples 
out of 103. For the rest of the samples, the concentration of NFH was below the limit of the 












5.2.4 Hypothesis five 
 
Hypothesis five stated that serum levels of the inflammatory markers neopterin, osteopontin 
and the neurodegenerative marker neurofilament H protein, would relate to cognitive function 
in HIV positive individuals; that is, highest levels would be measured in HIV positive patients 
with severe cognitive impairment, lower levels in mild to moderate impairment, and even 




To examine this hypothesis, the HIV positive participants were divided into their baseline 
cognitive function groups, and the median neopterin levels were then compared using a 
Kruskal-Wallis test. No significant difference was found (Table 5.34). Figure 5.5 shows the 
levels of neopterin across the groups in graphical form. 
 
Baseline cognitive function 
group 
Median serum neopterin level  
in ng/mL (IQR) 
Kruskal-Wallis Test 
Normal cognitive function  
GDS < 0.25 
(n = 37) 
3.86 (2.80) χ
2
 = 1.29 
df = 2 
p = 0.524 
Mild-Moderate Impairment 









Table 5.34: Comparison of median serum neopterin levels across the baseline cognitive 
function groups  
n = count; IQR = interquartile range; χ
2













Figure 5.5: Comparison of serum neopterin levels across the baseline cognitive function groups  
 
The median neopterin level of the cognitively normal group was compared to that in the 
severely impaired group, using a Wilcoxon rank-sum test. Again no significant difference was 
found. z = -1.11, p = 0.267. 
 
A different approach was attempted, which involved a median split of the neopterin values, 
which created “low” and “high” neopterin level categories for the HIV positive participants. 
These categories were then compared across the baseline cognitive function groups (see Table 
5.35), and a Pearson’s Chi-squared test performed to examine the effect. No significant 
difference was found. χ
2


















































Baseline cognitive function group 
Neopterin category (according to median split) 
Low High 
Normal cognitive function  
GDS < 0.25 
n = 21 n = 16 
Mild-Moderate Impairment 
0.25 ≤ GDS <0.75 
n = 17 n = 16 
Severe Impairment 
GDS ≥0.75 
n = 12 n = 18 
 
Table 5.35: Breakdown of numbers within high and low neopterin categories according to 
baseline cognitive function groups   
n = count 
  














Once again, the HIV positive participants were divided into their baseline cognitive function 
groups. The median osteopontin levels were then compared using a Kruskal-Wallis test. A 
significant difference was found (see Table 5.36). The group with mild to moderate cognitive 
impairment had slightly lower levels than the normal group, however the severe impairment 
group had the highest levels of osteopontin. Figure 5.6 shows this result in graph format. 
 
Baseline cognitive function 
group 
Median osteopontin level in  
pg/mL (IQR) 
Kruskal-Wallis Test 
Normal cognitive function  
GDS < 0.25 
(n = 37) 
232.00 (526.8) χ
2
 = 7.32 
df = 2 
p = 0.026 
Mild-Moderate Impairment 
0.25 ≤ GDS <0.75 





(n = 31) 
478.80 (1286.8) 
 
Table 5.36: Comparison of median serum osteopontin levels across the baseline cognitive 
function groups 
n = count; χ
2













Figure 5.6: Comparison of serum osteopontin levels across the baseline cognitive function 
groups 
 
The median osteopontin level of the cognitively normal group was compared to the severely 
impaired group, using a Wilcoxon rank-sum test. Again a significant difference was found.  
z = -2.11, p = 0.035. 
 
A median split of the osteopontin values was then performed, which created “low” and “high” 
osteopontin level categories for the HIV positive participants. These categories were then 
compared across the baseline cognitive function groups (see Table 5.37), and a Pearson’s Chi-
squared test performed to examine the effect. No significant difference was found. χ
2 
(2 df) = 

































































GDS < 0.25 
n = 21 n = 16 
Mild-Moderate 
Impairment 
0.25 ≤ GDS <0.75 
n = 19 n = 14 
Severe Impairment 
GDS ≥0.75 
n = 11 n = 20 
 
Table 5.37: Breakdown of numbers within high and low osteopontin categories according to 
baseline cognitive function groups   
n = count 
 
Serum levels of osteopontin did show some relation to cognitive function in HIV positive 
patients in this study. There was a significant difference between the normal cognitive function 
group and the severely impaired group, with the severely impaired group having markedly 
elevated levels. Interestingly, the mild to moderately impaired group had slightly lower levels 
than the normal cognitive function group.  
 
Neurofilament H protein 
 
Unfortunately the neurofilament heavy chain assays only yielded results for 2 of the samples 
out of 103. For the rest of the samples, the concentration of NFH was below the limit of the 












5.2.5 Hypothesis six 
 
Hypothesis six stated that higher initial serum levels of the proposed inflammatory and 
neurodegenerative markers would be associated with a change in cognitive function (as 
measured by the change in global deficit score) after approximately one year; such that higher 
initial marker levels would be associated with greater cognitive improvement one year later, 
after at least ten months on HAART, but in those patients not on HAART, higher initial serum 





For this analysis, all participants with both neopterin levels and follo -up data were included. 
n = 93. 
 
In examining the effect of baseline serum neopterin level on the change of cognitive function 
after one year, a difference in median neopterin level between the cognitive response groups 
was first looked for, using a Wilcoxon rank-sum test. A significant difference was found. Those 
who improved in cognitive function or maintained their cognitive function, had higher baseline 
serum neopterin level than those who worsened (see Table 5.38). Figure 5.7 shows this result 
in graph format. 
 
GDS change category Median baseline serum 
neopterin in ng/mL (IQR) 
Wilcoxon rank-sum test 
Maintained or improved 
cognitive function  
(n = 71) (76%) 
4.18 (4.09) z = 2.28 
p = 0.023 
Worsened cognitive  
function 
(n = 22) (24%) 
3.14 (2.02) 
 
Table 5.38: Comparison of median baseline serum neopterin level between the cognitive 
response groups 














Figure 5.7: Comparison of baseline serum neopterin level between the cognitive response 
groups 
 
A median split was once again applied. The difference in cognitive response was then 
examined for the two neopterin categories, and a Chi-squared test performed to assess the 
relationship. The actual median GDS change was also compared between the two groups using 
a Wilcoxon rank-sum test. A significant difference was found: more of those participants in the 
high neopterin level category maintained or improved their cognitive function than those with 
low neopterin levels (see Figure 5.8). The high neopterin group also had a greater 




































































Low  n = 32 n = 15 χ
2
 = 3.59 
df = 1 
p = 0.058 
0 (0.33) z = 2.39 
p = 0.017 High n = 39 n = 7 -0.165 (0.47) 
 
Table 5.39: Comparison of cognitive response and median GDS change between the high and 
low baseline serum neopterin categories (according to median split) 
n = count; χ
2




Figure 5.8: Comparison of GDS change between the high and low baseline serum neopterin 
categories 
 
NB: GDS change of ”0” implies maintenance of cognitive function; negative GDS change implies 
improvement; positive GDS change implies worsening 
 
A tertile split was done and the above analysis repeated (see Table 5.40). The group with high 
baseline neopterin levels still had significantly more participants who maintained or improved 




























































Low  n = 14 n = 10 p = 0.018 -0.065 (0.5) z = 1.625 
p = 0.104 High n = 20 n = 2 -0.165 
(0.47) 
 
Table 5.40: Comparison of cognitive response and median GDS change between the high and 
low baseline serum neopterin categories (according to tertile split) 
n = count; p = p value; z = statistic z; IQR = interquartile range 
 
The effect of HAART on the above was then analysed. n = 68 for these analyses as only those 
participants with neopterin results, and HAART data (either no HAART, or HAART for more 
than or equal to ten months) and CD4 count more than 350 cells/ul, could be included. No 
significant results were found (see Tables 5.41 and 5.42). 
  



















Low  n = 20 n = 5 p = 1.00 -0.07  (0.2) z = 0.709 
p = 0.478 High n = 24 n = 5 -0.13 (0.4) 



















Low  n = 4 n = 4 p = 0.301 0.035 (0.63) z = 0.91 
p = 0.362 High n = 5 n = 1 -0.065 (0.27) 
 
Table 5.41: Comparison of cognitive response and median GDS change between the high and 
low baseline serum neopterin categories, for the HAART and no HAART groups 
n = count; p = p value; z = statistic z 
 
Within the HAART and no HAART groups, no significant difference in terms of cognitive 
response was found, between the high and low baseline neopterin groups.  
 
Table 5.42 shows that there was no significant difference between the different combinations 











 Median GDS change (IQR) Kruskal-Wallis Test 
HAART, low neopterin (n = 25) -0.07 (0.2) χ
2
 = 2.27 
df = 3 
p = 0.518 
HAART, high neopterin  
(n = 29) 
-0.13 (0.4) 
No HAART, low neopterin  
(n = 8) 
0.04 (0.63) 
No HAART, high neopterin  
(n = 6) 
-0.07 (0.27) 
 
Table 5.42: Comparison of median GDS change across the different groups of HAART and 
neopterin level category 
n = count; IQR = interquartile range; χ
2
= Chi-squared; df = degrees of freedom; p = p value 
 
A Wilcoxon rank-sum test was also done to compare the HAART, high baseline serum 
neopterin group to the no HAART, high neopterin group, as specified in hypothesis six. There 
was no significant difference between the two groups.  z = -0.42, p = 0.670.  Table 5.43 shows 
the distribution of study participants across the HAART-neopterin level combination 
categories.   
 
 Maintained or improved 
cognitive function 
Worsened cognitive function 
HAART, low neopterin  n = 20 n = 5 
HAART, high neopterin n = 24 n = 5 
No HAART, low neopterin n = 4 n = 4 
No HAART, high neopterin n = 5 n = 1 
 
Table 5.43: Breakdown of numbers according to cognitive response across the different groups 
of HAART and neopterin level category 
n = count 
 
The findings in this study are partly in support of hypothesis six. That is, higher initial serum 
levels of neopterin were found to be associated with a change in cognitive function. Those 
with higher baseline neopterin levels were more likely to maintain or improve their cognitive 













For this analysis, all participants with both osteopontin levels and follow-up data were 
included. n = 93. 
 
In examining the effect of baseline serum osteopontin level on the change of cognitive 
function after one year, a difference in median osteopontin level between the cognitive 
response groups was first looked for. No significant difference was found (see Table 5.44 and 
Figure 5.9).  
 
GDS change category Median baseline serum 
osteopontin in pg/mL (IQR) 
Wilcoxon rank-sum Test 
Maintained or improved 
cognitive function  
(n = 71) 
269.8 (599.5) z = -0.44 
p = 0.658 
Worsened cognitive 
function (n = 22) 
322.15 (888.5) 
 
Table 5.44: Comparison of median baseline serum osteopontin level between the cognitive 
response groups 
n = count; IQR = interquartile range; z = statistic z; p = p value 
 
 















































A median split was once again applied. The difference in cognitive response was then 
examined for the two osteopontin categories, and a Chi-squared test performed to assess the 
relationship. The actual median GDS change was also compared between the two groups using 
a Wilcoxon rank-sum test. No significant differences were found. (See Table 5.45 and Figure 





















Low  n = 38 n = 9 χ
2
 =1.07 
df = 1 
p = 0.301 
-0.13 (0.2) z = 0.31 
p = 0.757 
High n = 33 n = 13 -0.13 (0.54) 
 
Table 5.45: Comparison of cognitive response and median GDS change between the high and 
low baseline serum osteopontin categories (according to median split) 
n = count; χ
2




Figure 5.10: Comparison of GDS change between the high and low serum osteopontin 
categories 
 
NB: GDS change of ”0” implies maintenance of cognitive function; negative GDS change implies 





































A tertile split was done (to be able to compare the extremes of the osteopontin levels) and the 
above analysis repeated. Again, no significant difference was found between the groups in 


















Low  n = 20 n = 5 χ
2
 = 0.18 
df = 1 
p = 0.675 
-0.07 (0.2) z = 0.67 
p = 0.506 
High n = 18 n = 6 -0.13 (0.61) 
 
Table 5.46: Comparison of cognitive response and median GDS change between the high and 
low baseline serum osteopontin categories (according to tertile split) 
n = count; χ
2
= Chi-squared; df = degrees of freedom; p = p value; z = statistic z 
 
The effect of HAART on the above was then analysed. n = 67 for these analyses as only those 
participants with neopterin results, and HAART data (either no HAART, or HAART ≥10 months) 
and CD4 count >350, could be included.  Within the HAART group, one significant difference 
was detected. More of those with a low osteopontin level maintained or improved cognitive 
function at one year, than those with high baseline osteopontin. No other significant results 
were found (see Table 5.47).  
 



















Low  n = 26 n = 2 p = 0.034 -0.13 (0.235) z= -0.86 
p = 0.388 High n = 17 n = 8 -0.07 (0.53) 



















Low  n = 4 n = 2 p = 0.657 0 (0.2) z = 0.13 
p = 0.897 High n = 5 n = 3 -0.07 (0.57) 
 
Table 5.47: Comparison of cognitive response and median GDS change between the high and 
low baseline serum osteopontin categories, for the HAART and no HAART groups 











 Median GDS change (IQR) Kruskal-Wallis Test 




 = 2.13 
df = 3 
p = 0.539 
HAART, high osteopontin  
(n =25) 
-0.07 (0.53) 
No HAART, low osteopontin  
(n =6) 
0 (0.2) 




Table 5.48: Comparison of median GDS change across the different groups of HAART and 
osteopontin level category 
n = count; χ
2
= Chi-squared; df = degrees of freedom; p = p value 
 
For the different combinations of HAART, no HAART, and high and low osteopontin, no 
significant difference was found in terms of median GDS change at one year (see Table 5.48). 
 
A Wilcoxon rank-sum test was also done to compare median GDS change in the HAART, high 
baseline serum osteopontin group to the no HAART, high serum osteopontin group. There was 
no significant difference between the two groups. z = -0.17, p = 0.866. Table 5.49 shows the 
distribution of participants across the HAART and osteopontin level categories.   
 
 Maintained or improved 
cognitive function 
Worsened cognitive function 
HAART, low osteopontin  n = 26 n = 2 
HAART, high osteopontin n = 17 n = 8 
No HAART, low osteopontin n = 4 n = 2 
No HAART, high osteopontin n = 5 n = 3 
 
Table 5.49: Breakdown of numbers according to cognitive response across the different groups 
of HAART and osteopontin level category 
n = count 
 
Overall, baseline serum osteopontin levels were not found to be related to the change in 
cognitive function at one year. 
 
Neurofilament H protein 
 











5.2.6 Hypothesis seven 
 
This hypothesis stated that higher initial serum levels of the proposed inflammatory and 
neurodegenerative markers would be associated with the change in cognitive function 
according to the CNS penetration-effectiveness of the HAART regimen used; that is, 
participants with higher initial serum levels of the proposed inflammatory and 
neurodegenerative markers, would have greater improvement in cognition if they were on 
HAART regimens with a CPE of more than seven, as opposed to regimens with a CPE of less 
than or equal to seven. 
 
The sample used to examine this hypothesis is small as only participants on HAART for at least 




Median GDS change was compared across the categories of high and low CPE versus high and 
low baseline serum neopterin level (according to a median split). A Kruskal-Wallis test was 
used for the comparison. Table 5.50 shows the result, which borders on significance, indicating 
that there could be a difference in cognitive response between the different categories of high 
and low neopterin and high and low CPE. 
 
 Median GDS change (IQR) Kruskal-Wallis Test 
Low CPE, low neopterin  
(n = 13) 
-0.13 (0.2) χ
2
 = 7.43 
df = 3 
p = 0.056 Low CPE, high neopterin  
(n = 12) 
     0 (0.24) 
High CPE, low neopterin  
(n = 12) 
-0.04 (0.43) 
High CPE, high neopterin  
(n = 17) 
-0.2 (0.34) 
 
Table 5.50: Comparison of median GDS change across the different groups of CPE and 
neopterin level categories 
n = count; χ
2
= Chi-squared; df = degrees of freedom; p = p value 
 
Two further comparisons were done. The high CPE, high neopterin was compared to the low 











rank-sum test was used to compare the medians of the two groups. No significant difference 
was found. z = 1.55, p = 0.122.    
 
The high CPE, high neopterin group was then compared to the low CPE, high neopterin group. 
A Wilcoxon rank-sum test was used to compare the medians of the two groups. A significant 
difference was found. z = 2.32, p = 0.020.  This finding is in support of hypothesis seven for 
neopterin, that is, higher baseline serum neopterin levels were associated with greater 
improvement in GDS in those who received HAART of a high CPE regimen, as opposed to those 




Median GDS change was compared across the categories of high and low CPE, versus high and 
low baseline serum osteopontin level (according to a median split). A Kruskal-Wallis test was 
used for the comparison. Table 5.51 shows the result. No significant difference was detected. 
 
 Median GDS change (IQR) Kruskal-Wallis Test 
Low CPE, low osteopontin  
(n = 11) 
-0.13 (0.20)  χ
2
 = 3.56 
df = 3 
p = 0.313 
Low CPE, high osteopontin  
(n = 13) 
       0 (0.40) 
High CPE, low osteopontin  
(n = 17) 
-0.13 (0.53) 
High CPE, high osteopontin  
(n = 12) 
-0.17 (0.47) 
 
Table 5.51: Comparison of median GDS change across the different groups of CPE and 
osteopontin level categories 
n = count; χ
2
= Chi-squared; df = degrees of freedom; p = p value 
 
Two further comparisons were done. The high CPE, high osteopontin was compared to the low 
CPE, low osteopontin group, as these groups represented the extreme situations. A Wilcoxon 
rank-sum test was used to compare the medians of the two groups. No significant difference 












The high CPE, high osteopontin group was then compared to the low CPE, high osteopontin 
group. A Wilcoxon rank-sum test was used to compare the medians of the two groups. No 
significant difference was found. z = 1.12, p = 0.260.   
 
No evidence in support of hypothesis seven was found for osteopontin; that is, the baseline 
serum levels of osteopontin did not relate to the change in cognitive function at one year, 
according to the CPE of the HAART regimen used.  
 
Neurofilament H protein 
 















The HIV positive group was found to be comparable to the HIV negative control groups. The 
only significant difference was in terms of level of education (attributable to the much higher 
level in the control group for the AD participants).  
 
Within the HIV positive group, the baseline cognitive function groups were found to be 
comparable in terms of CD4 count, sex and age. A significant difference was found only for 
level of education, in that those who were more impaired had had a lower level of education. 
These findings were also true for the smaller sub-group of participants with CD4 count less 
than 350 cells/ul and HAART data.  
 
The group who received HAART was comparable to that which did not receive HAART in terms 






The group who received HAART had significantly more participants with maintained or 
improved cognitive function, and a significantly greater improvement in GDS at the one year 
follow-up visit, than the group who had not received HAART. 
 
Those with higher GDS at baseline (that is poorer cognitive function) had a significantly greater 
improvement in GDS at the one year follow-up visit. The GDS change was greatest for those 




HAART was found to be protective of cognitive function. Amongst those participants with 
normal cognitive function at baseline, significantly more of those who received HAART 














No significant difference in cognitive response was found between the groups receiving HAART 




Serum neopterin levels were found to be significantly higher in the HIV positive group as 
compared to the HIV negative control groups. 
 
No significant difference was found for the osteopontin levels between the HIV positive group 
and the HIV negative control groups. 
 
Due to the assays yielding only very few detectable levels, the neurofilament H data were not 




Serum neopterin level was found not to relate to the level of cognitive function in the HIV 
positive group. 
 
Serum osteopontin levels showed some relation to cognitive function in the HIV positive 
group. That is, significantly higher levels were found in the severely impaired group as 




Baseline serum neopterin levels were found to be associated with the change in cognitive 
function at the one year follow-up visit. That is, significantly more of those with higher baseline 
serum neopterin levels maintained or improved their cognitive function at the one year follow-
up visit than those with lower baseline serum neopterin levels.  HAART status had no effect on 
this relationship. 
 
Baseline serum osteopontin levels were not associated with the change in cognitive function 














Higher baseline serum levels of neopterin were found to be significantly associated with the 
change in cognitive function after one year, according to the CPE of the HAART regimen used. 
The group with high baseline levels of neopterin together with a high CPE HAART regimen, had 
significantly greater improvement in cognitive function than the group with high baseline 
levels of neopterin together with a low CPE HAART regimen. 
 
No association was found for baseline serum osteopontin levels and change in cognitive 











Chapter 6 – Discussion 
 
This study investigated the effect of antiretroviral therapy on cognitive function in HIV positive 
individuals in Cape Town, South Africa. Furthermore, it sought to investigate a few potential 
serum biomarkers for HAND, to assist with diagnosis and potentially, prognostication in our 
setting.  
 
Overall, HAART was found to be beneficial in protecting, and in some cases, improving 
cognitive function. The CPE of the regimen used was not found to be an important factor in 
terms of cognitive outcomes, which is of local public health importance, given our recent ART 
protocol change.  
 
A suitable serum biomarker for use in HAND in South Africa was not identified, although some 
potentially clinically useful information was detected. Neopterin levels were higher in the HIV 
positive group than in the HIV negative controls. Neopterin did not relate to baseline cognitive 
function in the HIV positive group. However, higher baseline neopterin levels were associated 
with maintenance of, or improvement in, cognitive function after one year. Osteopontin levels 
did not differ significantly between the HIV positive and negative groups, but did relate to 
cognitive function in the HIV positive group, with highest levels found in the most severely 
impaired. Baseline osteopontin was not associated with change in cognitive function. In this 
study, neurofilament heavy chain was not present in the peripheral blood in a concentration 
that allowed detection.  
 
The following discussion first focuses on potential confounding factors arising from the 
demographic characteristics of the study participants, before commenting on the results of the 
hypotheses. Limitations of the study are then addressed before providing recommendations 
for future research. 
 
Study participant demographic characteristics 
 
The HIV positive group was found largely to be comparable to the HIV negative control groups.  
Besides age, which would clearly differ significantly given the vastly different target age ranges 
of the HAND study population and the AD study population, the only significant difference was 











older HIV negative, cognitively normal group. This group was however included only as a 
comparison for the AD participants’ findings, and was therefore not relevant as a control group 
for the HIV positive group. The younger, HIV negative control participants were recruited from 
the same demographic areas as the HIV positive participants, and according to the same 
criteria (besides HIV status). The fact that statistically significant differences in demographic 
features were found, is probably not clinically relevant given that these two groups merely 
represented different random samples from the same population.  
 
Within the HIV positive baseline cognitive function groups, a significant difference was also 
found in terms of education, in that those who were most severely impaired, had on average, 
the lowest level of education.  
 
The differing levels of education need further explanation.  
 
Firstly, the two study cohorts (HIV and AD) are from very different socio-economic 
backgrounds. Higher socio-economic status is often associated with increased level of 
education, which is reflected in the higher number of years amongst the older, cognitively 
normal control group.  
 
Secondly, lower level of education is a recognised risk factor for dementia (Stern 2009). This 
relates to the concept of cognitive reserve, which is basically the brain’s ability to sustain insult 
before the appearance of a functional deficit. In a systematic review conducted by Valenzuela 
and Sachdev, increased cognitive reserve was found to be associated with a significantly 
decreased risk for incident dementia (0.54 OR, CI 95% 0.49-0.59) (Valenzuela and Sachdev 
2006). Factors found to increase reserve were higher educational and occupational 
attainment, higher intelligence quotient, and mentally stimulating leisure activities (Valenzuela 
and Sachdev 2006; Stern 2009). Lower level of education has also been linked to increased risk 
of cognitive impairment in HIV in a number of studies (Joska et al. 2010b; Balestra et al. 2011). 
 
Thus, it is not surprising that the attained level of education was significantly lower in the 
severely cognitively impaired groups (for both HIV and AD) with respect to their cognitively 
normal, otherwise demographically similar control groups.  
 
It is also possible that level of education is in fact a confounding variable. That is, those with 











education, and were therefore less experienced with a test procedure, and not necessarily 
because they were more cognitively impaired. While this is concerning, the neuropsychological 
test battery remains the current gold standard for cognitive assessment. 
 
The effect of HAART on cognitive function (hypothesis one and two) 
 
The study of the effect of HAART on cognitive function in the immunosuppressed HIV positive 
population was opportunistic. Clearly, it would not have been ethical to purposefully withold 
HAART from this population (given HAART’s well known positive systemic effects on viral 
control and resultant immune reconstitution) merely for the sake of studying cognitive 
responses. However this study opportunity arose as a result of local circumstances.  
 
The very recent change in the South African National ART Guidelines, from a HAART initiation 
threshold of 200 cells/ul to 350cells/ul, meant that given the timing of the study, there was a 
sample of participants with a CD4 count less than 350cells/ul, who were not eligible for HAART 
in South Africa at that time.  
 
Secondly, there is unfortunately currently always a group of eligible people in South Africa who 
do not receive HAART as they should do. This is due to a number of factors, including, the vast 
number of HIV positive people in South Africa, the resultant high burden on the healthcare 
system, with a lack of adequate resources at many of the HIV clinics, as well as poor health 
education and residual HIV-associated social stigma. 
 
Given this population of CD4 count-matched HAART-naïve participants, it was possible to show 
that HAART is in fact beneficial for cognitive function. The groups needed to have comparable 
CD4 counts, as advanced immunosuppression and more specifically, lower nadir CD4 count, 
have been shown to be risk factors for HAND (Childs et al. 1999; Balestra et al. 2011; Ellis et al. 
2011). As the CD4 counts of the two compared groups (HAART and no HAART) were not 
significantly different, CD4 count (and therefore stage of disease) did not represent a 
confounding factor in this analysis. 
 
The finding in this study of HAART being beneficial for maintaining or improving cognitive 
function is consistent with current literature on the subject. HAART’s positive effect on 
cognition has previously been demonstrated in sub-Saharan Africa (Sacktor et al. 2006), and, 











HAART induces a significant improvement in cognitive status, typically within 6 months of 
treatment initiation (Joska et al. 2010a). Other recent literature has, however, questioned 
HAART’s positive effect on cognitive function, given the continually high incidence rate of 
HAND in the HAART era. Many reasons have been proposed (see 2.2.3.3, p22), including 
potential toxicity of the ARVs themselves. These hypotheses require further investigation. 
However, the results of this study support the use of HAART for the prevention and treatment 
of HAND in South Africa, amongst the immunocompromised HIV positive population, as more 
participants who received HAART maintained or improved cognitive function than those who 
did not receive HAART. 
 
HIV positive participants with higher global deficit score at baseline (that is, poorer cognitive 
function) had a greater improvement in GDS at the one year follow-up visit. The GDS change 
was greatest for those who were most severely impaired and received HAART. This is in 
agreement with the finding by Cysique et al. (2009) that severe baseline cognitive impairment 
was a predictor of neuropsychological improvement at follow-up. It is also consistent with 
previous observations which led to the clinical characterisation of HAD as a potentially 
reversible dementia (Nath et al. 2008). The reason that the most severely impaired 
participants had the greatest improvement in GDS could however merely reflect the fact that 
these participants had greater scope for improvement. One cannot become more “normal” 
than “normal”, therefore those who were mildly or moderately impaired, could only improve 
their GDS to a smaller degree than those who were more severely impaired at baseline.  
 
The overall analysis of cognitive response at the one year follow-up visit for all participants 
who completed follow-up, showed a high rate (75%) of a positive cognitive response; that is, 
maintenance or improvement in cognitive function. This most likely also reflects the positive 
effect of HAART on cognition, as 77% of the participants used in this analysis had been initiated 
on HAART since the baseline assessment. (HAART data were available for 111 of the 115 
follow-up participants. Of the 111, 89 had been initiated on HAART since the baseline 
assessment. Only 69 were used in the formal HAART response analysis as they needed to have 
been on one regimen only, for at least 10 months, which were requirements for the HAART 
hypotheses.)  
 
Neuropsychological improvement due to HAART therapy has been shown to be greatest for 
HAART-naïve individuals (Letendre et al. 2004), typically within six months of initiation of 











study. It has been hypothesised that the high level of inflammation found in HIV has a 
detrimental effect on cognition, relating to dysfunctional neurons, before actual cell death 
occurs. It is therefore possible that HAART is able to dampen this inflammatory response to 
some extent, by reducing the viral load, which allows for neuronal functional recovery, and 
therefore improvement in cognitive ability. 
 
Whilst practice effects must always be kept in mind with repetition of neuropsychological test 
batteries, the interval between the testing was long in this study, and the positive effect of 
HAART on cognition is biologically plausible. 
 
The effect of HAART regimen CNS penetration-effectiveness (CPE) on cognitive outcomes 
 
One of the proposed reasons for the continually high incidence rate of HAND in the HAART era 
relates to the difficulty posed by the blood-brain barrier for the passage of drugs into the CNS. 
The CPE ranking system was devised by Letendre et al (2008; revised 2010), according to the 
ability of different ARV agents to cross the BBB and achieve control of HIV replication within 
the CNS. However, studies looking at the correlation between cognitive outcomes and higher 
CPE regimens have shown mixed results (Tozzi et al. 2009; Rourke et al. 2011; Ciccarelli et al. 
2011; Letendre et al. 2004; Marra et al. 2009). Tozzi et al. and Letendre et al. both found an 
association between higher CPE regimens and improved neuropsychological function, Rourke 
et al., and Ciccarelli et al. found no association between CPE scores and cognitive outcomes, 
and Marra et al. found an association between higher CPE scores and poorer cognitive 
performance. 
 
This study found no association between the CPE of the HAART regimen used and the cognitive 
outcome at a one year follow-up assessment. Whilst this is in agreement with other 
international study findings, it is important to consider that the numbers for the CPE analysis in 
this study were small, and the length of follow-up relatively short. Given these factors, and the 
ongoing mixed results in the literature, it is still uncertain whether the CPE of the HAART 
regimen used is an important factor in treating HAND or not. The result of this study is 
however beneficial in terms of South African public health, given the recent ART protocol 
change, to a new first-line HAART regimen with a low CPE ranking of only six. Concerns have 
been raised about the potential impact on cognitive function, due to the widespread use of 
this regimen, however the findings in this study indicate that those concerns may have been 











HAND biomarker investigation 
 
This study sought to investigate HAND biomarkers further, especially for use in the South 
African setting. Blood was used instead of CSF for several reasons.  
 
Most importantly, at the time of the study’s initiation, the ethics committee had not granted 
permission for the collection of CSF for investigation as part of the study, as the participants 
were well out-patients, and lumbar puncture was deemed not otherwise clinically necessary, 
invasive, and potentially dangerous. Blood collection was given ethical approval, as it is 
considered minimally invasive and safe for the participants.  
 
The safety concerns associated with lumbar puncture will always be present for consideration 
in patient care. A blood biomarker would therefore be far better overall, especially for use in 
primary health care. Other considerations are the short time and minimal expertise required to 
take blood rather than CSF, which are important for a clinically feasible biomarker for the 
South African setting, where HIV care is often provided by nursing sisters at a primary level.   
 
CSF does naturally provide a closer reflection of what is occurring within the CNS, yet given the 
altered permeability of the BBB in HIV infection, it was hypothesised that the substances of 
interest would be detectable in the peripheral blood in sufficient levels for potential use as 
biomarkers. 
  
Serum neopterin in HAND (hypothesis four, five, six and seven) 
 
In this study serum neopterin levels were found to be significantly higher in the HIV positive 
group as compared to the HIV negative control groups. This was expected as it has been 
reported in the literature that neopterin levels are raised in the body fluids of HIV positive 
individuals throughout the course of their illness, rising with disease progression (Wirleitner et 
al. 2005). This reflects neopterin’s status as a marker for cellular immune activation, being 
produced by stimulated macrophages. The vast majority (120 out of 125) of the HIV positive 
participants in this study had a CD4 count of less than 350 cells/ul, indicating 
immunosuppression and an advanced stage of HIV disease. Therefore raised serum neopterin 












Serum neopterin level did not relate to the level of cognitive function in the HIV positive group 
in the current study. This contrasts with the findings of Hagberg et al. (2010) where blood 
neopterin levels were shown to have a correlation to cognitive function, in that higher levels 
were found in the more impaired patients when compared to the minimally impaired patients. 
Whilst this correlation was strong in the Hagberg study for CSF levels, the blood neopterin 
level-cognitive function correlation only held for participants with a CD4 count of more than 
200 cells/ul. Considering that the mean CD4 count in my study was 166 cells/ul, this could 
explain why no correlation with cognitive function was detected. 
 
Baseline serum neopterin levels were found to be associated with the change in cognitive 
function at the one year follow-up visit. That is, significantly more of those with higher baseline 
serum neopterin levels maintained or improved their cognitive function at the one year follow-
up visit than those with lower baseline serum neopterin levels.  HAART status had no effect on 
this relationship. This is an interesting and paradoxical finding. Higher serum neopterin levels 
have been found in several studies to be predictive of HIV disease progression (Hagberg et al. 
2010; Kitchen et al. 2008; Mildvan et al. 2005). Given the importance of inflammation in HIV 
disease pathogenesis, this makes sense. The findings in this study are therefore unexpected, as 
one would think that worsening inflammation would not predict cognitive improvement. 
Perhaps this is due to the fact that neopterin was measured in the blood rather than CSF, and 
was therefore not giving an accurate reflection of the inflammation occurring within the CNS. 
It would have been interesting to know what the serum neopterin levels were in the 
participants at the follow-up assessment. However, unfortunately no blood was collected at 
this time. That may have given a clearer indication of the true inflammatory trend.  
 
Should it have been that higher baseline neopterin levels correlated with greater cognitive 
improvement in those who received HAART, only, this would have been more logical. It could 
be that in those with greater levels of inflammation at baseline, there is greater scope for 
improvement with HAART, due to suppression of the inflammatory response. However, HAART 
status did not have an effect on the relationship between baseline serum neopterin and 
cognitive response at one year. It is, however, possible that this is merely a spurious finding, 
due to small numbers in this analysis (n = 68: 54 on HAART and 14 not on HAART). 
 
Higher baseline serum levels of neopterin were also found to be significantly associated with 
the change in cognitive function after one year, according to the CPE of the HAART regimen 











regimen, had significantly greater improvement in cognitive function than the group with high 
baseline levels of neopterin together with a low CPE HAART regimen. This is also an interesting 
finding, which suggests that perhaps this study does support the use of higher CPE regimens 
after all. The fact that the participants with higher baseline neopterin levels did better 
cognitively if they received a higher penetrating regimen, suggests that perhaps the increased 
HAART penetration was able to target the increased inflammation to a  greater degree (by 
allowing for better CNS viral control which would reduce the inflammatory stimulus), allowing 
for greater improvement in cognitive function. However, problems with this argument include 
that no clear benefit for the higher CPE regimen was seen when analysed alone, and 
considering the finding discussed in the previous paragraph it is unlikely that the serum 
neopterin levels are giving a clear reflection of the degree of CNS inflammation. It must be 
remembered, however, that this was a small study and perhaps the numbers are not reflecting 
the situation accurately, in which case any of the above may or may not be true findings. 
 
Serum osteopontin in HAND (hypothesis four, five, six and seven) 
 
In this study, no significant difference was found for the osteopontin levels between the HIV 
positive group and the HIV negative control groups. Chagan-Yasutan et al. found osteopontin 
to be raised in the plasma of HIV positive human individuals, with minimal decrease with 
HAART. Yet the numbers were very small in their study (n = 8) (Chagan-Yasutan et al. 2009).  
 
On simple inspection of the median values found in the current study, within the different 
study groups, no clear distinction was seen between the HIV positive and negative groups, but 
what was evident was that the HIV positive group and the AD group in fact both had lower 
levels overall than the two completely cognitively normal groups. This finding was not 
significant (p = 0.159), but is still perhaps an interesting observation that could be explored 
further in another study with larger numbers. Perhaps osteopontin may still have a role as a 
marker of cognitive dysfunction in neurodegenerative disorders.  
 
Serum osteopontin levels showed some relation to cognitive function in the HIV positive 
group. That is, significantly higher levels were found in the severely impaired group as 
compared to the normal cognitive function group. This is in partial agreement with the findings 
of Burdo et al. (2008) who found a significant correlation between plasma osteopontin levels 
and HIV CNS dysfunction. However in my study, the osteopontin levels did not increase 











current study the mild to moderately impaired group actually had slightly lower levels of 
osteopontin than the cognitively normal group (see table and graph on page 88 and 89). This 
could be an effect due to the divisions of the cognitive function groups; that is, the mild to 
moderately impaired group perhaps was too heterogeneous to group together. The normal 
and severely impaired groups clearly represent extremes, whilst the middle group in fact 
represents a spectrum of impairment in its own right. This could explain why a clear trend in 
terms of osteopontin level was not detected. 
 
The same study by Burdo et al. (2008) mentioned above, examined both humans and rhesus 
monkeys. The monkey component of the study also had a longitudinal arm looking at plasma 
osteopontin levels in relation to the development of simian AIDS and encephalitis. Here it was 
found that the plasma osteopontin levels increased before the onset of neurological 
abnormalities (Burdo et al. 2008), suggesting a predictive role for the substance. In my study, 
baseline serum osteopontin levels were not associated with the change in cognitive function 
one year later and therefore a predictive role in humans was not detected. 
 
Serum neurofilament heavy chain in HAND (hypothesis four, five, six and seven) 
 
In this study, neurofilament heavy chain was not present in the peripheral blood in a 
concentration that allowed detection. This is unfortunate as it would have been interesting to 
compare serum findings with those of Anderson et al. for the CSF (see page 33). 
 
Study limitations  
 
This study had limitations.  
 
Being partly opportunistic in utilising pre-existing information and serum samples as an 
adjunct to a larger study, this work was cost-effective. However the larger study had been 
initiated well before the time of this project. This meant that a lot of the work for this study 
had to be done retrospectively, and therefore the way that the participants were assessed, 
could not be altered. 
 
Ideally more blood could have been collected for storage for later assays; both an increased 
amount at the baseline assessment and a second sample at the follow-up assessment. This 











financial limitations in this regard), as well as allowing for a second measurement to give an 
indication of the trend of the analytes for each participant.  
 
The number of investigations done at baseline could also have increased, to attempt to 
exclude further possible asymptomatic opportunistic infections, especially given that serum 
inflammatory markers were being measured. There is a high prevalence of sub-clinical 
opportunistic infections within the HIV positive population in South Africa, reflected by the 
high rate of immune reconstitution inflammatory syndrome (IRIS) on HAART initiation (10% in 
one study, by Murdoch et al. (2008).  
 
This is linked to the issue of known negative, versus unknown, RPR status. The fact that the 
study participants were not tested as part of the formal study assessments was unfortunate, 
given the high rate of sexually transmitted infections in the South African population as a 
whole, and the even higher rate amongst the HIV positive population. Syphilis infection may 
also have neurological effects, although generally only with very advanced disease. Although it 
was attempted to remedy this omission by tracing the results of testing done at the local 
clinics or hospitals, it was not possible to find test results for all the participants. In the 
comparison between the two groups (RPR negative versus RPR unknown, see results table on 
page 66), they were found to be similar in terms of most factors except for cognitive function. 
Overall, the median baseline GDS was higher in the RPR unknown group (indicating worse 
cognitive function). Furthermore, the proportion of RPR unknown to RPR negative was greater 
in the cognitively impaired group, than in the other two baseline cognitive function groups 
(table on page 66). Whilst it is possible that there were a few positive RPR participants in the 
RPR unknown group, which could have been advanced syphilis with resulting cognitive 
dysfunction, it is more likely that the increased number of unknown RPRs in this severely 
impaired group, is due to decreased health seeking behaviour secondary to the already 
existing HIV-related cognitive impairment.   
 
All of the above noted, it is, however, important to remember that HIV positive individuals will 
probably always have sub-clinical infections contributing to a systemic inflammatory response, 
which has been hypothesised to be an important driver of CNS inflammation and 
neurodegeneration (Perry et al. 2007), so therefore possible undetected opportunistic 












There was a relatively short time-scale of follow-up. One year could be considered not quite 
long enough for assessing cognitive outcomes. Perhaps with a longer period of follow-up, a 
different response rate might have been detected, and potentially a difference in the high and 
low CPE regimens might also have become apparent. Other studies to determine the cognitive 
response to HAART have however utilised similar time frames for follow-up assessment, for 
example Cysique et al. (2009) did repeated neuropsychological testing at 12, 24, 36 and 48 
weeks after initiation of HAART. These researchers found a mean improvement in cognitive 
function with HAART, especially for those with higher CPE regimens. 
 
Perhaps the HIV negative demographically similar controls, who underwent 
neuropsychological testing to create the set of normal ranges for the study population, could 
have had repeat testing at one year. This would have allowed for a second set of normal 
ranges, which could have been used to control for improvement in GDS due to practice effects. 
 
Although there were sound reasons for using blood instead of CSF in the biomarker analysis, 
the most important being the lack of ethical approval for CSF collection at the time, this could 
be viewed as a limitation of the study. For the investigation of biological conditions within the 
CNS, cerebrospinal fluid is unrivalled due to its proximity to the brain. However, systemic 
inflammation does play a role in influencing the state of the CNS, and therefore the 
measurement of blood analytes still has an important role. Practical issues around CSF 
collection should also not be ignored when considering potential biomarkers. 
 
There were relatively small numbers in the study, although the numbers were adequate to 
yield some significant results. The relatively small study numbers are due to the poor follow-up 
rate, and limited time available to complete the study.  
 
The follow-up rate was considered as a possible source of bias: those who did not return for 
the follow-up assessment could have deteriorated significantly more than those who did 
complete follow-up. Reasons for this could include poor memory or severe apathy (both 
features of HAND). In this way, important trends may have been lost. However, it is also 
possible that some participants who had become significantly better in terms of cognition also 
did not return for follow-up. Education around this study being purely for research purposes 
and not for curative purposes, was given in the informed consent process. It is, however, 











involvement in this research. Thus those whose cognition improved markedly, may have no 
longer felt the need to return for follow-up.  
 
A brief analysis was therefore done on the greater study population to determine the baseline 
cognitive status of those who did not return for follow-up: 19% had normal cognitive function, 
38% had mild to moderate impairment and 43% had severe impairment. In contrast, the 
distribution of baseline cognitive status, amongst the participants who did return for follow-up 
was: 44% normal, 32% mild to moderately impaired and 23% severely impaired. These data 
reflect a fair distribution across the cognitive function groups. However, an inverse relation 
was seen with more initially cognitively normal participants returning for follow-up, and more 
initially severely impaired participants failing to return. Although unavoidable, this may 
indicate a selection bias in terms of follow-up, in favour of the participants with better 
cognition. 
 
However, the most likely reason for the overall poor follow-up rate is purely practical. These 
participants are from a low socio-economic background, meaning a stable dwelling and fixed 
contact telephone number are not standard. Poverty and the inability to lose a day of work 
could also be important factors in not returning to the study. It should be remembered too, 
that these participants all had HIV disease, mostly with advanced immunosuppression, and 
therefore death due to opportunistic infection was always a possibility. This may be true even 
more so for those with greater cognitive impairment, who could well have had more advanced 
HIV disease. 
 
Despite these limitations, this study has been worthwhile in producing further information on 
HAND as a clinical entity in South Africa. South Africa represents a high HIV prevalence area, 
but limited research is done here compared to the developed world. It is a region where clade 
C HIV-1 is found, which is relatively understudied compared to clade B. There is also a distinctly 
demographically different population to that found in the US and Europe, where the majority 
of HAND research is conducted, as well as a healthcare system which faces different 














Chapter 7 – Conclusions and recommendations 
 
Overall, this study has added to the pool of evidence which shows that HAART is beneficial for 
cognitive function. HAART regimen CPE was not found to be an important factor in cognitive 
outcomes after one year. This is a promising finding in the protocol-bound South African 
context, where the current first-line HAART regimen has a low CPE ranking. This study has 
however highlighted the need to focus on improving HAART initiation programmes to ensure 
that all those who are currently eligible are in fact receiving HAART.  
 
As the greater evidence base is still divided on the issue of whether higher CPE regimens are 
more beneficial for cognitive outcomes, further prospective CPE studies with larger samples 
and longer follow-up times need to be conducted, ideally, also within South Africa. 
 
Serum neopterin and osteopontin levels may have clinical use; however, further research is 
required to identify biomarkers for HAND in South Africa. Further studies looking at these and 
other potential markers (alone or in combination), in larger populations, and with serial levels, 
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